var textForPages = ["MIMS HANDBOOK OF\nGERIATRIC MEDICINE\n\n                                       Treatment Approaches\n\n                                                            2017\/2018\n\n                                                            Prescribe a Pharma Dynamics product.                                            LARGEST\n\n                                                            It\u2019s a smart call.                                                             CVS\n\nCALCIUM CHANNEL BLOCKERS                ANTIPLATELET        THIAZIDE-LIKE       SULPHONYLUREA     \u00df BLOCKERS                                COMPANY\n                                        Pharma Dynamics         DIURETIC                                                                       IN SA1\n\n amlodipine           nifedipine       clopidogrel           SR 1,5 mg          SR 30 mg               carvedilol     bilocor\n5 mg, 10 mg         30 mg, 60 mg              75 mg                                               6,25 mg, 12,5 mg,\n                                                                                                                     bisoprolol fumarate\n                                                                                                        25 mg           5 mg, 10 mg\n\nACE INHIBITORS                         ACE \/ DIURETIC       STATINS                               \u03b1 BLOCKER          \u00df BLOCKER \/ DIURETIC\n\nPearinda             enap               Pearinda             simvastatin         atorvastatin     doxazosin 4 mg         bisoprolol\n perindopril tert-                                          10 mg, 20 mg,       10 mg, 20 mg,                        fumarate \/ HCTZ\n    butylamine      enalapril maleate    perindopril tert-                      40 mg, 80 mg                         2,5 mg \/ 6,25 mg\n    4 mg, 8 mg        5 mg, 10 mg,         butylamine \/         40 mg                                                 5 mg \/ 6,25 mg\n                          20 mg            indapamide                                                                10 mg \/ 6,25 mg\n\n                                         4 mg \/ 1,25 mg\n\nPDE5 INHIBITOR      ANGIOTENSIN II RECEPTOR BLOCKERS                            ARB \/ DIURETIC\n\n   sildena\ufb01l         telmisartan          irbesartan        losartan potassium       losartan     valsartan \/ HCTZ\n50 mg, 100 mg       40 mg, 80 mg       150 mg, 300 mg         50 mg, 100 mg     potassium \/ HCTZ  80 mg \/ 12,5 mg\n                                                                                50 mg \/ 12,5 mg   160 mg \/ 12,5 mg\n                                                                                100 mg \/ 25 mg     160 mg \/ 25 mg\n\nCUSTOMER CARE LINE 0860 PHARMA (742 762) www.pharmadynamics.co.za\n\nAMLOC 5 and 10 mg. Each tablet contains amlodipine maleate equivalent to 5, 10 mg amlodipine respectively. S3 A38\/7.1\/0183, 0147. NAM NS2 06\/7.1\/0011, 0012. BILOCOR 5 and 10. Each tablet contains 5, 10 mg bisoprolol\nfumarate respectively. S3 A38\/5.2\/0053, 0051. NAM NS2 06\/5.2\/0061, 0062. BILOCOR CO 2,5\/6,25, 5\/6,25, 10\/6,25. Each tablet contains 2,5, 5, 10 mg bisoprolol fumarate respectively and 6,25 mg hydrochlorothiazide. S3\nA44\/7.1.3\/1010, 1011, 1012. NAM NS2 13\/7.1.3\/0260, 0261, 0262. CARVETREND 6,25, 12,5, 25 mg. Each tablet contains 6,25, 12, 25 mg carvedilol respectively. S3 A37\/7.1.3\/0276, 0277, 0278. NAM NS2 08\/7.1.3\/0105,\n0104, 0103. CARZIN XL. Each tablet contains 4 mg doxazosin. S3 A41\/7.1\/0557. NAM NS2 10\/34\/0376. PHARMA DYNAMICS CLOPIDOGREL 75 mg. Each tablet contains 75 mg clopidogrel. S3 A42\/8.2\/0128. NAM NS2\n10\/7.1\/0377. DYNAFIL 50 and 100 mg. Each tablet contains 50, 100 mg sildena\ufb01l respectively. S4 A42\/7.1.5\/1071, 1072. NAM NS2 13\/7.1.5\/0086, 0087. DYNA GLICLAZIDE SR 30 mg. Each tablet contains 30 mg gliclazide.\nS3 A42\/21.2\/0249. NAM NS2 12\/21.2\/0110. DYNA INDAPAMIDE SR. Each tablet contains 1,5 mg indapamide. S3 A42\/7.1\/0790. NAM NS2 12\/7.1\/0138. DYNARB 150 mg. Each tablet contains 150, 300 mg irbesartan\nrespectively. S3 A43\/7.1.3\/0720, 0721. NAM NS2 12\/7.1.3\/0223, 0224. DYNATOR 10, 20, 40, 80 mg. Each tablet contains 10, 20, 40, 80 mg atorvastatin respectively. S4 A43\/7.5\/0167, 0168, 0169, 0170. NAM NS2\n13\/7.5\/0111, 0112, 0113, 0114. DYNAVAL CO 80\/12,5, 160\/12,5, 160\/25 mg. Each tablet contains 80, 160, 160 mg valsartan respectively and 12,5, 12,5, 25 mg hydrochlorothiazide respectively. S3 A44\/7.1.3\/0018, 0019,\n0020. NAM NS2 14\/7.1.3\/0061, 0062, 0063. ENAP 5, 10, 20 mg. Each tablet contains 5 mg enalapril maleate respectively. S3 A34\/7.1.3\/0085, 0086, 0087. NAM NS2 04\/7.1.3\/1138, 1137, 1136. FEDALOC 30 and 60 mg\nSR. Each tablet contains 30, 60 mg nifedipine respectively. S3 A37\/7.1\/0302, 0303. NAM NS2 10\/7.1\/0033, 0034. PEARINDA 4 and 8. Each tablet contains 4, 8 mg perindopril tert-butylamine respectively. S3 A41\/7.1.3\/0649,\n0650. NAM NS2 10\/7.1.3\/0476, 0477. PEARINDA PLUS 4. Each tablet contains 4 mg perindopril tert-butylamine and 1,25 mg indapamide. S3 A41\/7.1.3\/0633. NAM NS2 10\/7.1.3\/0611. SIMVACOR 10, 20, 40 mg. Each\ntablet contains 10, 20, 40 mg simvastatin respectively. S4 A35\/7.5\/0237, 0238, A39\/7.5\/.0132. NAM NS2 04\/7.5\/1660, 1659, 07\/7.5\/0166. TESAR 40 and 80 mg. Each tablet contains 40, 80 mg telmisartan respectively. S3\nA45\/7.1.3\/0978, 0979. NAM NS2 17\/7.1.3\/0023, 0024. ZARTAN 50 and 100 mg. Each tablet contains 50, 100 mg losartan potassium respectively. S3 A41\/7.1.3\/0287, 0289. NAM NS2 08\/7.1.3\/0067, 0086. ZARTAN CO\n50\/12,5 and 100\/25. Each tablet contains 50, 100 mg losartan potassium and 12,5, 25 mg hydrochlorothiazide respectively. S3 A42\/7.1.3\/1068, 1069. NAM NS2 12\/7.1.3\/0070, 0071. For full prescribing information, refer to\nthe package insert approved by the Medicines Control Council. 1) IMS MAT Units Dec 2016. CVSG366\/04\/2017.","Flexible Dose. Precise Control.\n\n                        In the treatment of Hypothyroidism\n                                  prescribe Euthyrox\u00ae\n\n                       45,7 % of patients may require a 12,5 \u03bcg or 25 \u03bcg\n                             dosage in order to be optimally titrated 1\n\n                            Reimbursed by major Medical Aids\n\nReference: 1. Oosthuizen H, Smuts PF, et al. Structured Levothyroxine Dose Titration to Achieve Euthyroidism Poster. DeuTSH Study.\n\nProprietary Name (and dosage form): Euthyrox\u00ae 25 \u00b5g \/ Euthyrox\u00ae 50 \u00b5g \/ Euthyrox\u00ae 100 \u00b5g Tablets. Composition: Each Euthyrox\u00ae tablet contains 25 \u00b5g \/ 50 \u00b5g \/ or 100 \u00b5g\nlevothyroxine sodium.\n\nRegistration details:  South Africa      Namibia           Botswana\nEuthyrox\u00ae 25 \u00b5g        S3 A39\/21.3\/0401  NS2 11\/21.3\/0135  S2 BOT1302362B\nEuthyrox\u00ae 50 \u00b5g        S3 A39\/21.3\/0402  NS2 11\/21.3\/0136  S2 BOT1302363B\nEuthyrox\u00ae 100 \u00b5g       S3 A39\/21.3\/0403  NS2 11\/21.3\/0137  S2 BOT1302364B\n\nFor full prescribing information please refer to the package insert approved by the Medicines Regulatory Authority. MERCK (Pty) Ltd. Reg. No.1970\/004059\/07. 1 Friesland\nDrive, Longmeadow Business Estate South, Modderfontein, 1645. Tel. (011) 372-5000, Fax. (011) 372-5252. Report adverse events to drug.safety.southeastafrica@merckgroup.com\nSEA\/EUT\/0117\/0003","MIMS HANDBOOK\nOF GERIATRIC MEDICINE\n\n                    Treatment Approaches","ii                                Prof Jaques R Snyman\n                                  MBChB M Pharm Med MD\n    Credits\n                                  Silke Friedrich\n         Editor-in-Chief\t\n         \t                        Lynette Strydom\n         Business Manager\t\n         Publishing Editor\t       Dr Jaco Lotriet\n         CPD Compiler\t            BPharm, PhD (Pharm)\n         \t\n         Advertising Executives\t  Barbara Milroy\n         \t                        Loren Chimes\n         Production Manager\t\n         Designer\t                Mercy Baloyi\n         \t\n         GM: Magazines\t           Tanya Pretorius\n         Printer\t                 Thursday\u2019s Cat Media\n         Publisher\t\n         \t                        Jocelyne Bayer\n         \t\n         \t                        CTP Book Printers, Cape Town\n         \t\n         \t                        MIMS (Times Media Limited)\n                                  P O Box 1741\n                                  Saxonwold\n                                  2132\n                                  Tel (011) 280 5873\n\nCopyright \u00a92017 MIMS [A division of Times Media (Pty) Ltd] ISBN: 978-0-9947184-0-2\nThis book is copyright. Apart from any fair dealing for the purposes of private study, research,\ncriticism or review as permitted under the Copyright Act, no part may be reproduced by any\nprocess without written permission.\n\n   The opinions expressed in MIMS Handbook of Geriatric Medicine are those of the contributing\nauthors and do not necessarily reflect the opinion of the publisher.\n\n   MIMS [a division of Times Media (Pty) Ltd] is an independent company and is not affiliated to\nany pharmaceutical manufacturer or professional association. The advertising carried in MIMS\nHandbook of Geriatric Medicine is independent of and has no influence over the editorial content.\n\n   Although every effort has been made in compiling, editing and checking the information\ngiven in this publication to ensure that it is accurate, the authors, the editors, the publisher and\nits employees or agents shall not be responsible for the continued currency of the information,\nor for any errors, omissions or inaccuracies in this publication, whether arising from negligence or\notherwise, or for any consequences arising therefrom. Readers should consult the Information for\nPrescribers, as well as the manufacturers\u2019 package inserts, for indications, dosages and\/or other\nrelevant information.\n\nHANDBOOK OF GERIATRIC MEDICINE","iii\n\nContents\n\nInformation for Prescribers viii...................................................................................................................................\n\nTREATMENT APPROACHES\n\nCardiovascular conditions\n\nAntihypertensives 1................................................................................................................................................................\nProf IG Okpechi\nCardiovascular risk in type 2 diabetes mellitus and\nnew treatment options 9.................................................................................................................................................\nDr A Kok\nCommon cardiac conditions in the elderly 14...............................................................................\nDr GE Letcher\nDeep vein thrombosis 22...............................................................................................................................................\nDr D Reddy\nIschaemic heart disease \u2013 a sub-Saharan African perspective....................28\nProf M Ntsekhe, Dr K Lukhna\nRisk of cardiovascular disease in women 36....................................................................................\nProf IG Okpechi\nAcute myocardial infarction, unstable angina and stable angina.......... 44\nProf M Ntsekhe\n\nEndocrine conditions\n\nInitiating and titrating basal insulin treatment in patients\nwith type 2 diabetes 52....................................................................................................................................................\nDr M Koning\nErectile dysfunction in men over 65 55........................................................................................................\nDr E Rudolph, CN Boffard\nHormone therapy in peri- and postmenopausal women 61.......................................\nProf LC Snyman\nManagement of type 2 diabetes in the elderly 65....................................................................\nDr EF Delport\n\nNeuropsychiatric conditions\n\nDementia and delirium 72.............................................................................................................................................\nMs K Mayimele, Prof B Chiliza\nDiagnosis and management of generalised anxiety disorder\nand panic disorder in adults 80............................................................................................................................\nDrs AB Locke, N Kirst, CG Shultz\n\nHANDBOOK OF GERIATRIC MEDICINE","iv\n\n          Clinical vignettes in geriatric depression 89.......................................................................................\n           Dr GD Spoelhof, Dr GL Davis, Dr A Licari\n          Normal and abnormal sleep in geriatric patients 100.........................................................\n           Dr AJ Bentley\n\n          Musculoskeletal conditions and pain\n\n          Osteoarthritis 107......................................................................................................................................................................\n           Prof AA Kalla\n          Osteoporosis 114........................................................................................................................................................................\n           Dr AJ de Weerd\n          Gait and balance disorders 118..........................................................................................................................\n           Dr J Smuts\n          Clinical pharmacology of corticosteroids: use in the elderly 123.......................\n           Prof JR Snyman\n          Chronic pain in the aged 127.................................................................................................................................\n           Dr S Chetty\n\n          Pulmonary conditions\n\n          Chronic obstructive pulmonary disease in the elderly 133...........................................\n           Prof DJV Weich\n          Acute lung infections in the elderly 140....................................................................................................\n           Prof DJV Weich\n          In\ufb02uenza: prevention, treatment and vaccine indications 146..............................\n           Dr C Cohen\n\n          Dermatological and aesthetic conditions\n\n          Hair loss in the elderly 154...........................................................................................................................................\n           Dr CN Davies\n          Photo-ageing lesions including solar keratosis\/actinic keratosis 159...........\n           Dr M Smit\n          Varicose veins 172.................................................................................................................................................................\n           Dr N le Grange\n\n          Visual impairment\n\n          Glaucoma 178.............................................................................................................................................................................\n           Prof D Meyer\n          Age-related macular degeneration 187................................................................................................\n           K Panesar\n\n           HANDBOOK OF GERIATRIC MEDICINE","KeenMindR\n\n                                                        Calm focus, memory & cognitive function\n\n                                                        Clinically proven\n\nKeenMind is clinically proven to:\n\n  P enhance memory retention and recall1-3\n  P improve focus & mental clarity1-3\n  P reduce anxiety (anxiolytic effect)1-3\n  P reduce forgetfulness3\n\n    Available without prescription at leading\n    pharmacies and health shops.\n\n   www.flordis.co.za | Tel 044 874 2927\n\nReferences: 1. Stough, et al. Psychopharmacology. 2001;156:481-484. 2. Roodenrys, et al. Neuropsychopharmacology. 2002;27:279-281. 3. Stough, et al. Phytotherapy Research. 2008;22:1629-1634. \u00ae KeenMind is a registered trademark of Flordis Pty Ltd.","vi\n\n          Urinary system conditions\n          Benign prostatic hyperplasia 195.......................................................................................................................\n           Dr W Lambrechts\n          Incontinence in ageing individuals 198....................................................................................................\n           Dr W Lambrechts\n          Oncology screening and care\n          Cancer screening in the elderly patient \u2013 general guidelines.....................203\n           Dr D Eedes\n          Cancer screening in the elderly patient \u2013 specific guidelines.....................209\n           Dr D Eedes\n          General\n          The use of assistive devices 216...........................................................................................................................\n           Dr M de Villiers\n         SUBJECT INDEX 222..............................................................................................................................................................\n\n           HANDBOOK OF GERIATRIC MEDICINE","","viii\n\n      Information for Prescribers\n\n      When prescribing any product mentioned       n\tAll entries have been compiled stric-\n      in MIMS Handbook of Geriatric Medicine,          tly in accordance with the current\n      doctors should be mindful of the impor-          package inserts in the publisher\u2019s\n                                                       possession.\n      tant points listed below.\n      n\tHypersensitivity to the ingredient(s)\/    n\tM o n o - a m i n e o x i d a s e i n h i b i t o r s\n                                                       (MAOIs) have a prolonged action, so\n          components of any medicine contra-           patients should not take any of the\n          indicates its use.                           foods or medicines known to cause\n                                                       reactions for at least 14 days after\n      n\tMedicines should not be prescribed to         stopping treatment.\n          pregnant or lactating women unless the\n          anticipated benefit clearly outweighs    n\tCertain medicines (i.e. those that\n          any potential risk to the foetus.            cause CNS depression) may lead to\n                                                       drowsiness and impaired concentra-\n      n\tThe possibility of drug accumulation          tion, which may be aggravated by\n          should be considered in the pres-            the simultaneous intake of alcohol or\n                                                       depression agents.\n          ence of significant renal or hepatic\n                                                   n\tAll editorial has been compiled by\n          impairment.                                  authorities in their respective field, and\n                                                       opinions expressed are not necessarily\n      n\tTolerance to medicines is likely to be        those of the publisher, its employees,\n                                                       agents or editors. Some indications\n          less with extremes of age.                   and\/or dosages described in the\n                                                       articles may therefore differ from the\n      n\tSide effects refer only to those which        registered package insert of the rele-\n                                                       vant product. MIMS does not promote\n          occur at the recommended dosages             or take responsibility for the \u201coff-label\u201d\n          and correct route of administration.         use of medicines, but allows for the\n      n\tDrug interferences with laboratory            publication of new or evidence-based\n          tests and physical incompatibilities         information. Health-care professionals\n          common with parenteral solutions             are to use this information at their\n          have not been included.                      discretion, and are referred to current\n      n\tDosages given are for adults only             manufacturer product literature for\n          unless otherwise stated. For additional      registered indications and dosages.\n          information on dosage directions,\n          particularly in the case of parenteral\n          products, consult the MIMS Desk\n          Reference where applicable, the\n          pharmaceutical company or the\n          current package insert.\n\n      HANDBOOK OF GERIATRIC MEDICINE","Risk of cardiovascular disease in women 1\n\nAntihypertensives                                                                            TREATMENT APPROACHES\n\nProf IG Okpechi                              proper measurement of blood pressure\nMBBS, FWACP, PhD (UCT), Cert Nephrol         (BP), the difficulty often lies with decid-\nPhD(SA) Phys                                 ing when to commence therapy\n\uf072\t Associate Professor and Director of       and what agent(s) should be used for\nResearch, Division of Nephrology and         treatment.\nHypertension and the Kidney and\nHypertension Research Unit, Department       INDICATIONS FOR DRUG THERAPY:\nof Medicine, University of Cape Town         hypertension without compelling\n                                             indications for specific agents\nHypertension is an important public health\nchallenge of global proportions. It repre-   Figure 1 provides a summary of the indica-\nsents one of the most important modifiable   tions for drug therapy in adult hypertensive\nrisk factors for preventing cardiovascular   patients, according to the Southern\ndisease (CVD) and death.                     African hypertension guidelines. The indi-\n                                             cations for therapy are:\n  Drug treatment of the hypertensive         n\t A ntihypertensive therapy should be\npatient is in constant evolution in respon-\nse to available new data and guidelines          prescribed for average diastolic blood\npublished every year by researchers,             pressure (DBP) of \u2265100\u202fmmHg or\npharmaceutical industries and various            average systolic blood pressure (SBP)\nexperts in this field. As the diagnosis of       of \u2265160\u202fmmHg in patients without\nhypertension can be easily made by the           macrovascular target organ damage\n                                                 or other cardiovascular risk factors.\n\nFigure 1. Southern African hypertension management flow diagram\nbased on added CVD risk\n\n            Stratify according to added risk BP level + major risk factors + TOD +\n                                     established CV\/renal disease\n\nLow added risk             Moderate added risk                    High\/very high added risk\n\n                           Lifestyle modification as appropriate\n\nMonitor BP and other risk  Monitor BP and other risk\nfactors for 6 -12 months   factors for 3-6 months\n\nSBP \u2265140        SBP <140   SBP <140             SBP \u2265140\nor DBP \u226590                                      or DBP \u226590\n                and DBP <90 and DBP <90\n\n                Continue to monitor\n\n                                                                         Begin drug\n                                                                         treatment\n\n                                                HANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","Common cardiac conditions in the elderly 21\n\nn\t Anticoagulation                                         reactive cellular hypertrophy. Circ Res.            TREATMENT APPROACHES\n\t \u2013\tUsually mandated in the very                           1991;68:1560-1568.\n                                                      11.\tW ong LS, et al. Aging, telomeres and heart\n         elderly, but there may be contra-                  failure. Heart Fail Rev. 2010;15:479-486.\n         indications, in which case one               12.\tL akatta EG, Levy D. Arterial and cardiac\n         could consider a left atrial                       aging: major shareholders in cardiovas-\n         appendage closure device.                          cular disease enterprises: Part II: the aging\n                                                            heart in health: links to heart disease.\nVentricular dysrhythmias                                    Circulation. 2003;107:346-354.\nn\t These are usually haemodynamically                13.\tPandya K, et al. Fibrosis, not cell size, deline-\n                                                            ates beta-myosin heavy chain re-expres-\n    important, and require urgent treat-                    sion during cardiac hypertrophy and\n    ment, or, if not available, referral.                   normal aging in vivo. Proc Natl Acad Sci\n                                                            USA. 2006;103:16864-16869.\nSee Figure 2 for the Vaughan-Williams                 14.\tC hen W, Frangogiannis NG. The role of\nClassification of anti-arrhythmic drugs.                    inflammatory and fibrogenic pathways in\n                                                            heart failure associated with ageing. Heart\nREFERENCES                                                  Fail Rev. 2010;15:415-422.\n1.\tLevy D, et al. Long-term trends in the inci-    15.\tU delson JE. Heart failure with preserved\n                                                            ejection fraction. Circulation. 2011;124.\n      dence of and survival with heart failure. N     16.\tK omajda M, et al. Contemporary manage-\n      Engl J Med. 2002;347:1397-1402.                       ment of octogenarians hospitalized for\n2.\tBleumink GS, et al. Quantifying the heart             heart failure in Europe: Euro Heart Failure\n      failure epidemic: prevalence, incidence               Survey II. Eur Heart J. 2009;30:478-586.\n      rate, lifetime risk and prognosis of heart      17.\tBarsheshet A, et al. Predictors of long-term\n      failure. The Rotterdam Study. Eur Heart J.            (4-year) mortality in elderly and young\n      2004;25:1614-1619.                                    patients with acute heart failure. Eur J\n3.\tJugdutt BI. Prevention of heart failure in the        Heart Fail. 2010;12:833-840.\n      elderly: when, where and how to begin?          18.\tM ogensen UM, et al. Clinical characteris-\n      Heart Fail Rev. 2012;17:531-544.                      tics and major comorbidities in heart failure\n4.\tRoger VL, et al. Trends in heart failure inci-        patients more than 85 years of age\n      dence and survival in a community-based               compared with younger age groups. Eur J\n      population. JAMA. 2004;292:344-350.                   Heart Fail. 2011;13:1216-1223.\n5.\tGoldberg RJ, et al. Trends in mortality         19.\tK elder JC, et al. The diagnostic value of\n      attributed to heart failure in Worcester,             physical examination and additional\n      Massachusetts, 1992 to 2001. Am J Cardiol.            testing in primary care patients with\n      2005;95:1324-1328.                                    suspected heart failure. Circulation.\n6.\tFonarow GC. Epidemiology and risk stratifi-           2011;124:2865-2873.\n      cation in acute heart failure. Am Heart J.      20.\tB arsheshet A, et al. Applicability of a risk\n      2008;155:200-207.                                     score for prediction of the long-term\n7.\tManzano L, et al. Predictors of clinical              (8-year) benefit of the implantable cardio-\n      outcomes in elderly patients with heart               verter-defibrillator. J Am Coll Cardiol. 2012;\n      failure. Eur J Heart Fail. 2011;13:528-536.           59:2075-2079.\n8.\tNieminen MS, et al. EuroHeart Failure           21.\tInglis SC, et al. Structured telephone\n      Survey II (EHFS II): a survey on hospitalized         support or telemonitoring programmes for\n      acute heart failure patients: description of          patients with chronic heart failure.\n      population. Eur Heart J. 2006;27:2725-2736.           Cochrane Database Syst Rev. 2010;8.\n9.\tForman DE, et al. Influence of age on the       22.\tA hmed A. DEFEAT \u2013 heart failure: a guide to\n      management of heart failure: findings from            management of geriatric heart failure by\n      Get With the Guidelines-Heart Failure                 generalist physicians. Minerva Med. 2009\n      (GWTG-HF). Am Heart J. 2009;157:1010-1017.            Feb;100(1):39-50.\n10.\tO livetti G, et al. Cardiomyopathy of the      23.\tB rignole M, et al. Guidelines on manage-\n      aging human heart. Myocyte loss and                   ment (diagnosis and treatment) of\n                                                            syncope. Eur Heart J. 2001;22:1256-306.\n\n                                                      HANDBOOK OF GERIATRIC MEDICINE","22 CARDIOVASCULAR CONDITIONS\n\nDeep vein thrombosis\n\nDr D Reddy                                    induration that occurs in up to 40\u202f% of\nMBChB (UCT) FC Cardio (SA)                    cases after a DVT.\n\uf072\t Consultant Surgeon: Department of\nCardiothoracic Surgery, Inkosi Albert         PATHOPHYSIOLOGY\nLuthuli Central Hospital, Durban\n                                              Lower limb DVT is well known to most\nDeep vein thrombosis (DVT) remains a          patients, and has spurred the creation of\ncommon yet often misdiagnosed clinical        the term \"economy class syndrome\",\nentity, with an annual incidence of           which refers to the risk factor of prolonged\napproximately 67 per 100 000 amongst the      immobilisation, hypoxia and dehydration\ngeneral population. Between 1\u202f% and 8\u202f%       experienced during long-haul flights.\nof patients who develop pulmonary             Virchow's triad remains the basis of the\nembolism will die, whereas others will        aetiological factors, namely endothelial\nexperience long-term complications such       injury, stasis or turbulence of blood flow,\nas post-thrombotic syndrome (40\u202f%) and        and hypercoagulability. These factors\nchronic thrombo-embolic pulmonary             may, in isolation or together, set in motion\nhypertension (4\u202f%).1                          the coagulation cascade.\n\n  Whilst venous thrombo-embolism is             Virtually all patients treated for venous\npredominantly a disease of the elderly,       thrombo-embolism have at least one risk\npeaks in incidence occur in the younger       factor. Untreated, the resultant thrombus\nage group in the neonatal period, and the     generally propagates and may embolise\ndisease is associated with pregnancy or       to the pulmonary vasculature via the right\nthe use of oral contraceptives in adoles-     side of the heart. Spontaneous thrombolysis\ncent women. Following hip or knee surgery,    and recanalisation of the vein then occurs\nthe incidence of DVT is estimated to be       in the natural course of the disease, with\nbetween 40\u202f% to 60\u202f%, and the risk of fatal   D-dimers being a degradation product of\npulmonary embolism between 2\u202f% to 7.5\u202f%       a cross-linked fibrin clot, and hence one of\nwithout pharmacological prophylaxis.2         the biomarkers of this process. As\n                                              mentioned, a proportion of patients will\n  DVT classically involves the lower limbs,   suffer from the long-term consequences of\nwith upper limb involvement uncommon          post-thrombotic syndrome.\nin the absence of an indwelling intrave-\nnous catheter or an intrinsic thrombophilia.  DIAGNOSIS\nLower limb DVT is classified as proximal\n(thigh or popliteal veins) or distal (calf    Traditionally, the diagnosis of DVT was\nveins involved). While proximal segment       reliant upon a suggestive history com-\nDVTs are associated with as high as a 50\u202f%    bined with non-specific clinical features,\nincidence of pulmonary embolism if            such as swelling, pain, loss of function and\nuntreated,                                    a positive \"Homan\" sign. Diagnostic clinical\n                                              signs are notoriously unreliable, particu-\n  DVTs confined to the calf are associated    larly in the obese patient, or an individual\nwith a less than 1\u202f% risk of pulmonary        with an immobilised limb following pelvic\nembolism and less than 20\u202f% risk of prox-     or orthopaedic surgery.\nimal propagation3. Limb complications\nsuch as venous gangrene, phlegmasia             The current diagnostic approach\nalba dolens and phlegmasia cerulea            attempts to rationalise the economic\ndolens may require intervention by a          burden of unnecessary investigations,\nvascular surgeon. Post-thrombotic             whilst cognisant of the potential conse-\nsyndrome (or post-phlebitic syndrome) is a    quences of a delayed or mixed diag-\nchronic entity characterised by leg           nosis, and the associated medico-legal\nswelling, pain, venous ectasia, and skin      implications.\n\nHANDBOOK OF GERIATRIC MEDICINE","PRADAXA\u00ae is now\n                        indicated for acute\n                        treatment and\n                        prevention of VTE*4\n\nFor patients with VTE\ndisease transitioning from heparin...\n\nTHE EVIDENCE\nADDS UP TO\n\nPRADAXA\u00ae1\n\nYOUR FORESIGHT.\n\nTHEIR FUTURE.\n\n*Venous Thromboembolism\nReferences: 1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran Versus Warfarin in\nThe Treatment of Acute in Venous Thromboembolism. N Engl J Med. 2009; 361: 2342-52.\n2. Pradaxa Package Insert. Ingelheim Pharmaceuticals (Pty) Ltd.\nS4 Pradaxa\u00ae 150 mg. Each capsule contains 150 mg of dabigatran etexilate base (as mesilate salt).\nReg. No. 45\/8.2\/0162. For full prescribing information refer to the package insert approved by the\nmedicines regulatory authority.\nApplicant details:\nIngelheim Pharmaceuticals (Pty) Ltd, 407\nPine Ave, Randburg. Tel: +27 (011) 348 2400.\nCpy. Reg. No. 1966\/008618\/07.\nBI Ref. No. GPM-PX-0022-ZA","24 CARDIOVASCULAR CONDITIONS\n\n  The clinician is directed to investigations    Venous ultrasonography is non-invasive,\nusing a combination of diagnostic              safe, accessible, relatively inexpensive\nacumen, knowledge of pretest probability       and is the investigation of choice in\nscores, and by adopting an evidence-           patients stratified as DVT-likely. Contrast\nbased approach to diagnosis and                venography is rarely utilised as it is inva-\ntreatment. In the past, a liberal approach     sive, painful, and is associated with\nto imaging resulted in only 10-25\u202f% of         vessel-wall damage, radiation exposure\npatients suspected of having a DVT actu-       and contrast-induced renal dysfunction.\nally having ultrasonographic evidence of       Impedance plethysmography and\nDVT. Serial ultrasound imaging, except in      magnetic resonance imaging (MRI) are of\nthe context of specific sub-groups (such       little use in the clinical setting.\nas pregnant women), has also proven\ninefficient1.                                    The fundamentals of the diagnostic\n                                               algorithm for DVT (see Figure 1) in current\n  A widely used clinical prediction model,     clinical practice includes establishing the\nthe Wells score, takes into account the        pretest probability of a DVT, combined\nclinical features and risk factors for DVT,    with the results of a D-dimer assay, and\ncategorising patients as having a low,         finally (and usually unequivocally) imaging\nmedium or high probability of DVT2. This       in the form of compression ultrasound with\nmodel has been shown to be reproduc-           Doppler2. Imaging further enables the\nible, and allows identification of patients    operator to localise the extent of the\nwho do not require primary or serial ultra-    disease, and is extremely useful in the\nsonography (see Table 1).                      evaluation of a suspected recurrent DVT in\n                                               a previously afflicted limb.\n  D-dimer levels are elevated in acute\nthrombo-embolism, as well as in patients       PROPHYLAXIS\nwith a variety of nonthrombotic condi-\ntions, such as recent major surgery,           DVT prophylaxis may be mechanical or\npregnancy or trauma. The D-dimer assay is      pharmacological. Mechanical methods\na useful test to exclude DVT in patients       such as intermittent pneumatic compres-\nwith a low pretest probability of DVT,         sion devices and graduated compression\nparticularly in the outpatient setting.        stockings enhance blood flow in the deep\n\nTable 1. Pretest probability assessment (Wells score)\n\nClinical feature                                                        Score*\n\nActive cancer (treatment ongoing or within previous 6 months or palliative) 1\n\nParalysis, paresis, or recent plaster cast immobilisation of the lower  1\nextremities\n\nRecently bedridden for three days or major surgery within 12 weeks requiring 1\ngeneral or regional anaesthesia\n\nLocalised tenderness along the distribution of the deep veins           1\n\nEntire leg swollen                                                      1\n\nCalf swelling 3 cm >asymptomatic side (measured 10 cm below tibial      1\ntuberosity)\n\nPitting oedema limited to the symptomatic leg                           1\n\nCollateral superficial veins (nonvaricose)                              1\n\nAlternative diagnosis as likely as or more likely than DVT              -2\n\n* Interpretation:\t 0\t = low probability\t       3\u202f% frequency of DVT\n\t 1-2\t = medium probability\t                   17\u202f% frequency of DVT\n\t >3\t = high probability\t                      75\u202f% frequency of DVT\n\nHANDBOOK OF GERIATRIC MEDICINE","Deep vein thrombosis 25\n\nFigure 1. Algorithm for diagnosing DVT using clinical assessment, D-dimer testing,            TREATMENT APPROACHES\nand venous ultrasonography\n\n                        Clinical features and risk factors (DVT)\n\n                        Clinical probability\n\nDVT unlikely                                   DVT likely\n(probability score \u22641)                         (probability score >1)\n\n   D-dimer assay                                      Venous USS\n\nNegative  Positive                              Positive          Negative\n\nDVT       Venous USS                           Diagnose\/          D-dimer assay\nexcluded                                       treat DVT\n\n                                                          Negative Positive\n\n            Positive    Negative                          DVT          DVT follow-up\n                                                          excluded     studies\n          Diagnose\/     DVT                                            (repeat venous\n          treat DVT     excluded                                       USS in a week\n                                                                       or venography\n\nveins of the leg, preventing venous stasis     Fondaparinux, an indirect selective inhib-\nand thrombosis. The risk of venous thrombo-    itor of factor Xa, requires once-daily\nembolism and post-thrombotic syndrome          dosing and has a predictable response\nare reduced by 50\u202f% with the use of gradu-     that does not require monitoring of\nated compression stockings following           prothrombin times or partial thrombo-\nproximal DVT2. Pharmacological prophy-         plastin time. Dabigatran, an oral univalent\nlaxis consists of unfractionated heparin       direct thrombin inhibitor, and rivaroxaban,\n(UH), low molecular weight heparin             a once-daily potent and selective oral\n(LMWH), fondaparinux, oral direct selective    factor Xa inhibitor, require no laboratory\nthrombin inhibitors and factor Xa inhibitors.  monitoring due to the predictable antico-\n                                               agulant effect. Rivaroxaban, a new oral\nThe benefits of LMW heparin over unfrac-       direct factor Xa inhibitor, started six to\ntionated heparin include2:                     eight hours after total hip and knee joint\nn\t G reater bioavailability                   replacement surgery, was more effective\nn\t Predictability and dose-dependent          than enoxaparin started the previous\n                                               evening in preventing symptomatic\n    plasma level                               venous thrombo-embolism and all-cause\nn\t Less risk of bleeding                      mortality, without increasing major\nn\t L ower incidence of heparin-induced        bleeding4. Aspirin as monotherapy is\n                                               generally not recommended for thrombo-\n    thrombocytopenia                           prophylaxis for any patient group. The\nn\t L ower risk of heparin-induced             duration of thromboprophylaxis varies\n                                               between 10 to 35 days in patients at high\n    osteoporosis                               risk for venous thrombo-embolism (VTE)\nn\t No need for laboratory monitoring          such as following hip or knee surgery, and\nn\t C an be safely administered in             is generally continued until discharge in\n                                               patients with an acute medical illness.\n    outpatient setting\nn\t Duration of anticoagulant effect is                       HANDBOOK OF GERIATRIC MEDICINE\n\n    longer, permitting once- or twice-daily\n    administration","26 CARDIOVASCULAR CONDITIONS\n\nTREATMENT                                       therapy. Whilst warfarin remains the drug of\n                                                choice in long-term anticoagulation\nThe goal of DVT treatment is to prevent         following DVT, LMWH is preferred in preg-\nthe extension of thrombus and pulmonary         nancy due to the risks of teratogenicity and\nembolism in the short term, and to prevent      foetal haemorrhage. In patients with cancer,\nrecurrent thrombotic events and late            LMWH may also be preferred due to the\ncomplications (pulmonary hypertension           improved efficacy in preventing venous\nand post-thrombotic syndrome) in the            thrombosis without increasing bleeding risk,\nlong term3. Initial treatment comprises         as well as ease of management during inva-\nheparin (unfractionated or low molecular        sive procedures such as biopsies and\nweight) to achieve a critical therapeutic       indwelling central line placement.\nratio within the first 24 hours of treatment \u2013\nan activated partial thromboplastin time          The standard intensity of oral anticoagu-\n(aPTT) of 1.5 times the control value. Low      lation therapy is an international norma-\nmolecular weight (LMW) heparin enables          lised ratio (INR) of 2.0 to 3.0, which\nhome treatment, which results in an             prevents recurrent thromboses and\nimproved quality of life for patients and       decreases the risk of post-thrombotic\ncost savings for the health-care system.        syndrome. Low-intensity therapy (main-\nInpatient management may, however, be           taining an INR of 1.5-1.9) is ineffective in\nrequired for associated comorbidities,          preventing recurrent DVT, and is not asso-\npatients at risk of bleeding, and extensive     ciated with a reduction in the risk of\nDVT with local complications, such as           bleeding. The duration of anticoagulation\nphlegmasia cerulea dolens that requires         remains a constant area of interest, with\nparenteral pain control. LMW heparin has        current guidelines based upon the risk of\na more predictable anticoagulant effect,        recurrent DVT (see Table 2).3\nthus avoiding the need to assess pro-\nthrombin times, and is associated with a          The newer generation of oral antico-\nlower risk of heparin-associated throm-         agulants that do not require monitoring,\nbocytopaenia.                                   such as dabigatran and rivaroxaban,\n                                                may also be suitable options for long-\n  Warfarin therapy should be com-               term anticoagulation. Oral rivaroxaban,\nmenced on day one, and heparin                  at a dose of 15\u202fmg twice daily for the first\n(unfractionated or LMW) discontinued            three weeks, followed by 20\u202fmg once\nafter four to five days when the INR is         daily thereafter, without the need for\ngreater than 2.0 for two consecutive days.      laboratory monitoring, was as effective\nMonotherapy with warfarin ab initio is          and safe as standard therapy and may\ninsufficient due to the early prothrombotic     provide a single-drug approach to the\ntendency following warfarin introduction,       initial and continued treatment of venous\nand heparin must be used to initiate            thrombosis.5\n\nTable 2. Recommendations for the duration of anticoagulation for DVT\n\nEpisode of DVT  Cause                                      Duration\nFirst                                                      3-6 months\n                Reversible or time-limited risk factors \u2013\nFirst           surgery, trauma, short-term immobility,    3-6 months\nFirst           oestrogen replacement                      At least 6 months\nFirst                                                      12 months to lifetime\n                Heterozygous thrombophilias\nRecurrence                                                 Lifetime\n                Idiopathic\n\n                Malignancy (until resolved),\n                antiphospholipid antibody, combined or\n                homozygous genetic defects\n\nHANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","","","","","","Acute myocardial infarction, unstable angina and stable angina 51\n\n      cardiovascular disease in the developing       6.\tWhite HD, Chew DP. Acute myocardial            TREATMENT APPROACHES\n      world: global implications. Eur Heart J. 2010        infarction. Lancet. 2008 Aug 16; 372 (9638):\n      Mar; 31(6):642-8.                                    570-84.\n3.\tAbrams J. Clinical practice. Chronic stable\n      angina. N Engl J Med. 2005 Jun 16;352          7.\tBoden WE, Eagle K, Granger CB. Reper-\n      (24):2524-33. Review. No abstract avail-             fusion strategies in acute ST-segment\n      able. Erratum in: N Engl J Med. 2005 Dec             elevation myocardial infarction: a compre-\n      22;353(25):2728.                                     hensive review of contemporary mana-\n4.\tSnow V, Barry P, Fihn SD, et al. Primary care         gement options J Am Coll Cardiol. 2007\n      management of chronic stable angina                  Sep 4;50(10):917-29.\n      and asymptomatic suspected or known\n      coronary artery disease: a clinical practice   8.\tVan de Werf, Bax J, Betriu A, et al. Mana-\n      guideline from the American College of               gement of acute myocardial infarction in\n      Physicians. American College of Physicians;          patients presenting with persistent\n      American College of Cardiology Chronic               ST-segment elevation: the Task Force on\n      Stable Angina Panel. Ann Intern Med. 2004            the Management of ST-Segment Ele-\n      Oct 5;141(7):562-7. Erratum in: Ann Intern           vation Acute Myocardial Infarction of the\n      Med. 2005 Jan 4;142(1):79.                           European Society of Cardiology. Eur\n5.\tFox K, Garcia MA, Ardissino D, et al. The             Heart J. 2008 Dec;29(23):2909-45. Epub\n      Task Force on the Management of Stable               2008 Nov 12.\n      Angina Pectoris of the European Society of\n      Cardiology. Guidelines on the manage-          9.\tKalra S, Duggal S, Valdez G, et al. Review of\n      ment of stable angina pectoris: executive            acute coronary syndrome diagnosis and\n      summary: The Task Force on the                       management. Postgrad Med. 2008\n      Management of Stable Angina Pectoris of              Apr;120(1):18-27.\n      the European Society of Cardiology. Eur\n      Heart J. 2006 Jun;27(11):1341-81.              10.\tHamm CW, Bassand JP, Agewall S, et al.\n                                                           The Task Force for the management of\n\n                                                           acute coronary syndromes (ACS) in\n\n                                                           patients presenting without persistent\n\n                                                           ST-segment elevation of the European\n                                                           Society of Cardiology. Eur Heart J. 2011\n\n                                                           Dec;32(23):2999-3054.\n\n                                                     HANDBOOK OF GERIATRIC MEDICINE","52 ENDOCRINE CONDITIONS\n\nInitiating and titrating basal insulin\ntreatment in patients with type 2 diabetes\n\nDr M Koning                                  Step 1 recommends metformin and life-\nMBChB MMed (Int Med)                         style changes. Basal insulin can be added\n\uf072\t Specialist endocrinologist in private     in Step 2 or Step 3, where basal insulin is\npractice, Pretoria                           added as a third drug.4\n\nType 2 diabetes mellitus (T2DM) is a           Evidence from clinical trials shows that\nchronic disease that causes significant      early introduction of basal insulin is effec-\nmicro- and macrovascular complications       tive at keeping glucose levels within the\nwhen suboptimally treated. It affects more   target range with doses of <0.4 U\/kg\/day,\nthan 350 million people worldwide and        resulting in a low risk of hypoglycaemia\nthe prevalence is increasing rapidly,        and only moderate weight gain.3,5\nparticularly in developing countries. It is  However, when insulin is only initiated at a\ncrucial that patients are managed opti-      later stage, the dose required to achieve\nmally to decrease the risk of these          optimal glucose control is much higher,\ncomplications.                               resulting in an increased risk for hypogly-\n                                             caemia and excessive weight gain.3\nINITIATING INSULIN                           Long-term studies investigating the effect\n                                             of intensive glycaemic control cardiovas-\nIf a patient does not reach the goals for    cular (CV) outcomes have produced\nglycaemic control on oral agents, adding     mixed results. A meta-analysis including\na basal insulin to the regime should be      these trials suggests that intensive glucose\nconsidered. The goal for HbA1c varies        control reduces the risk of CV complica-\naccording to different guidelines. The       tions without increasing mortality \u2013 at least\nEASD, IDF and German Diabetes Asso-          in some patients.3 The ORIGIN study\nciation recommend a target of <6.5\u202f%,        showed that insulin therapy does not\nwhile the ADA recommends a target of         increase the risk of complications in\n<7\u202f%.1 Locally, the Society for Endo-        people with T2DM and CV-risk factors.3\ncrinology, Metabolism and Diabetes for\nSouth Africa (SEMDSA) recommends a           BARRIERS AGAINST INITIATION\ntarget of <7\u202f% for HbA1c for the majority    OF (BASAL) INSULIN\nof patients, a fasting glucose of\n4-7 mmol\/L and a postprandial glucose of     Failure to start basal insulin may be due to\n5-10\u00a0mmol\/L. The goal is <6.5\u00a0mmol\/L for     several factors, including fear (of the\nyoung patients with newly diagnosed          patient and the physician); especially fear\ndiabetes and no complications and            of hypoglycaemia, as well as a fear of\n<7.5\u00a0mmol\/L for the elderly, high-risk       weight gain.1 Physicians are often reluc-\npatients or those with hypoglycaemia         tant to initiate insulin, as they lack\nunawareness. 4 The target for elderly and    confidence in the patient\u2019s ability to\nfrail patients has to be less stringent, to  manage insulin therapy, or because of\nreduce the complications of hypogly-         uncertainties regarding initial insulin\ncaemia.3 It is therefore important to take   dosing and titration. Patients may also\ninto account the individual patient\u2019s age,   have several other barriers to insulin initia-\ncomplications, comorbidities and risk of     tion, such as a lack of self-confidence to\nhypoglycaemia when deciding about the        manage insulin therapy, psychological\ntarget that should be aimed for. 2           insulin resistance (PIR), a need for frequent\n                                             blood-glucose monitoring and pain asso-\n  In the SEMDSA Guidelines of 2012, a        ciated with insulin use.1 In insulin-na\u00efve\nstep-wise approach for the management        patients, PIR is common, and contributes\nof T2DM is recommended.                      to long delays in initiating insulin and\n\nHANDBOOK OF GERIATRIC MEDICINE","Initiating and titrating basal insulin treatment in patients with type 2 diabetes 53\n\nextensive periods of hyperglycaemia.2                e.g., if the patient\u2019s fasting blood                        TREATMENT APPROACHES\nSeveral studies showed the benefit of                glucose is 12\u00a0mmol\/L, the starting dose\nearlier rather than later addition of basal          will be 12 U.)\ninsulin. These benefits should be explained      n\t Target for fasting blood glucose:\nto the patient and might help overcome               5.6\u00a0mmol\/L\nthe barriers.                                    n\t Insulin titration: increments of 2 U at a\n                                                     time\nBASAL INSULIN TITRATION                          n\t Insulin titration frequency: every third day\nALGORITHMS                                       n\t Driver of titration: patients are as good\n                                                     (and even better) than physicians. In\nWhen the decision is made to initiate                one study they reached their targets in a\ninsulin therapy, it makes sense to first             shorter time period.\ntarget fasting glycaemia, as it contributes\nthe most to HbA1c.1 This can be done by          If the patient\u2019s HbA1c remains above target,\nadding a basal insulin or insulin analogue       in spite of target fasting glucose reached,\n(such as glargine or Levemir) to metformin,      prandial insulin should be added.\nwith or without the continuation of a\nsulphonylurea. In most studies, this combi-      REFERENCES\nnation improved glycaemic control,               1.\tArnolds S, et al. Common standards of\nwithout causing severe hypoglycaemia or\nexcessive weight gain. In a large, pooled              basal insulin titration in T2DM. J Diabetes Sci\nanalysis of prospective, randomised,                   Technol. 2013:7(3):771-788.\ncontrolled clinical trials in patients with      2.\tOvre D and Fonseca V. Benefits of timely\nT2DM, more than half of the patients previ-            basal insulin control in patients with type 2\nously uncontrolled on up to two oral                   diabetes. J of Diabetes and its Com-\nagents with baseline HbA1c of between                  plications. 2015;29:295-301.\n8.7 and 9.1\u202f% achieved a target HbA1c of         3.\tH a n e f e l d M . U s e o f i n s u l i n i n t y p e 2\n<7\u202f% 24 weeks after starting basal insulin.5           diabetes: What we learned from recent\n                                                       clinical trials on the benefits of early insulin\nRECOMMENDATIONS                                        initiation. Diabetes and Metabolism.\n                                                       2014;40:391-399.\nMost of the studies made the following           4.\tAmod A, et al. The 2012 SEMDSA Guideline\nrecommendations :1                                     for the management of Type 2 diabetes.\nn\t Starting dose: 10 U per day                        JEMDSA. 2012:17(2), Supplement 1:S1-S95.\n                                                 5.\tFonseca V, et al. An analysis of early insulin\n    (Alternatively, the patient\u2019s fasting blood        glargine added to metformin with or\n    glucose can be used as a guide,                    without sulfonylurea: impact on glycaemic\n                                                       control and hypoglycaemia. Diabetes,\n                                                       Obesity and Metab. 2011;13:814-822.\n\n                                                 HANDBOOK OF GERIATRIC MEDICINE","","Erectile dysfunction in men over 65 55\n\nErectile dysfunction in men over 65                                                             TREATMENT APPROACHES\n\nDr E Rudolph                                    the prevalence of erectile dysfunction\nMHSSH; PGDip CBT                                globally by 2025, with the biggest\n\uf072\t Psychosexologist, London                     increase in developing countries that\n                                                have expanding populations, such as\nCN Boffard                                      South Africa.\nMHSSH; PGDip CBT\n\uf072\t Psychosexologist, London                     IMPACT ON SOCIETY\n\n\u201cA man is only as old as his arteries\u201d          Erectile dysfunction has been found to\n\u2013 Sir William Osler                             have a great impact on a man\u2019s overall\n                                                quality of life and wellbeing, affecting his\nErectile dysfunction is the persistent          self-esteem, sexual desire and personal\ninability to attain or maintain an erection     relationships.8 A man experiencing this\nsufficient for sexual performance1 and is       may feel shock, despair, embarrassment,\nthe result of a problem within the complex      loss of vitality, fear of failure, frustration\ninteraction between the hormonal,               and a sense of hopelessness.9 These\nvascular and neurological process in the        emotions could lead to risk-taking behav-\nmale body.2 This experience can cause           iours, such as smoking, drinking and\nthe individual marked distress. It is a condi-  substance abuse, as well as the develop-\ntion that affects men both physically and       ment of challenging psychological\npsychologically; having a great impact on       symptoms. It is widely known that mental\none\u2019s wellbeing, quality of life and            health concerns have a great impact on\npersonal relationships.3 Although it is not     society, and erectile dysfunction has also\nlife-threatening, it is considered a marker     been found to be both a cause and\nfor other physical conditions, such as          effect of depression, with symptoms of\ncardiovascular disease.1 Even as early as       depression such as anhedonia, change\nthe1940s, Alfred Kinsey indicated that          in sleeping patterns and selective focus\nageing was a significant risk factor for        of negative experiences confounding\ndeveloping erectile dysfunction.2               the issue.2\n\nPREVALENCE                                        In studies that have assessed the quality\n                                                of life pre- and post-treatment for erectile\nIt is a widely known fact that as a man         dysfunction, the results continuously show\nages, his likelihood of developing erectile     that patients report an improvement in\ndysfunction increases.2 Various studies         overall sexual response, including desire,\nhave shown that in a general adult popu-        arousal and orgasm. Sexual satisfaction\nlation in the United States, 18-31\u202f% of men     and quality of life have also been shown\nare affected by erectile dysfunction, and       to improve. This has been found to posi-\nthis increases to 78\u202f% in men over 75,4,5       tively affect partners as well2 since\nUnfortunately, in South Africa there is a       erectile dysfunction can have a\npaucity of data on this particular popula-      profoundly negative effect on both the\ntion. Studies, such as that of De Klerk, have   patient and his partner.3\nfound prevalence rates of 77\u202f% in a black\nand mixed-race urban population in the            Studies conducted in the United States\nWestern Cape.6 The largest study ever           and the United Kingdom have explored\nconducted on ageing in men was the              the financial burden that the problem\nMassachusetts Male Ageing Study,7               places on society, with results showing\nwhich although conducted nearly 20              that the cost of erectile dysfunction\nyears ago, projected a 111\u202f% increase in        increases with male ageing.2,10 It was\n                                                found that outpatient visits and treatment-\n                                                seeking behaviour accounted for the\n\n                                                               HANDBOOK OF GERIATRIC MEDICINE","56 ENDOCRINE CONDITIONS\n\ngreatest proportion of costs, and genito-      n\t Previous sexual history, including issues\nurinary consultations and treatment                of gender identity or sexual orientation\nmeasures, such as prostheses, accounted\nfor a lower proportion. The impact of the      n\t Daily and nocturnal tumescence\nproblem is further compounded by the           n\t Partner issues, i.e., history of trauma,\nhigh correlation to other serious condi-\ntions, such as diabetes mellitus,                  sexual dysfunction or psychosocial issues\ncardiovascular disease, hypertension,          n\t Lifestyle, i.e., substance use, smoking,\ndepression or problems with the prostate,\nsuch as benign prostatic hyperplasia or            alcohol intake, exercise\nprostate cancer.2 This places a further\neconomical strain on the health-care           A genital examination should be\nsystem. In order to better evaluate the        performed by an appropriate clinician,\ncost of such a dysfunction, Wessells et al10   especially in the case of penile curvature\nsuggest that a better understanding of         during tumescence, Peyronie\u2019s disease,\ntreatment-seeking behaviour, patient-          painful erections, symptoms of hypog-\ntreatment preference, satisfaction and         onadism or any urological symptoms.1\noverall outcome, and a better under-\nstanding of pathogenesis is necessary. For       The International Index of Erectile\nthe South African population, the afford-      Function (IIEF) can be used as a diagnostic\nability of PDE-5 inhibitors has only recently  tool, and has become a standard meas-\nimproved, making treatment of erectile         urement in clinical trials.13 Ideally, men in\ndysfunction more accessible to many            relationships should be assessed with their\npopulation groups, but certainly not all.      partners present, as Hackett et al1 suggest\n                                               that co-existing sexual concerns, sexual\nDIAGNOSTIC ISSUES                              satisfaction and sexual health can thus be\n                                               identified and managed. They further\nFor all clinicians, erectile dysfunction       suggest that it is highly likely that all couples\nshould be taken seriously, as it has repeat-   will have some psychological element\nedly been shown to be an independent           contributing to their problem, and there-\nmarker for serious cardiovascular risk or      fore almost all couples could benefit from\ndiabetes mellitus.1 Investigations should      basic psychosexual education.1 This should\nthoroughly assess a man\u2019s personal,            take place following the initial assessment,\nmedical and lifestyle history and should       if not during. By helping a couple under-\ncommence with identifying reversible risk      stand the pathophysiology, aetiology,\nfactors, such as smoking, hyperlipidaemia,     physiological and psychological effects of\nhypogonadism and hypertension.                 the problem on their relationship, it could\nCorrecting these, could greatly reduce         ultimately improve the compliance and\none\u2019s risk.1                                   outcome of treatment.\n\n  When assessing a male patient for              Levinson14 suggested, \u201ceach cultural\npossible erectile dysfunction, a clinician     group in South Africa has different diag-\nshould conduct a thorough sexual               nostic acceptability\u201d. In many cultures, a\nhistory.11 This should include questions       psychogenic aetiology is considered\nregarding:                                     unacceptable, and according to\nn\t O riginal precipitating factors and date   Levinson, traditional Western medicine\n                                               tends to focus on how the condition\n    of onset                                   develops and how to treat it; rarely why it\nn\t P redisposing factors                      has developed. Furthermore, psycho-\nn\t Maintaining factors                        therapy is considered more acceptable\nn\t Medical history, including medical,        among the white population than African\n                                               cultures. Therefore, in treating older South\n    psychiatric and surgical history           African males, cultural considerations and\nn\t P revious erectile capacity                expectations should be taken into\nn\t Current relationship status                account and managed when suggesting\n                                               treatment options. This should be discuss-\nHANDBOOK OF GERIATRIC MEDICINE                 ed in detail with the patient.","","","","","","","","","","","","","","","","","","","","","","","","","Diagnosis and management of generalised anxiety disorder and panic disorder in adults 81\n\nTable 1. Diagnostic criteria for generalised anxiety disorder                                                             TREATMENT APPROACHES\n\nA.\t Excessive anxiety and worry (apprehensive expectation), occurring more days\n     than not for at least 6 months, about a number of events or activities (such as work\n     or school performance).\n\nB.\t T he individual finds it difficult to control the worry.\n\nC.\t T he anxiety and worry are associated with three (or more) of the following six\n     symptoms (with at least some symptoms having been present for more days than\n     not for the past 6 months):\n\n       Note: Only one item is required in children.\n\n       1.\t R estlessness or feeling keyed up or on edge.\n\n       2.\t Being easily fatigued.\n\n       3.\tDifficulty concentrating or mind going blank.\n\n       4.\tIrritability.\n\n       5.\t Muscle tension.\n\n       6.\t S leep disturbance (difficulty falling or staying asleep, or restless, unsatisfying\n             sleep).\n\nD.\t T he anxiety, worry, or physical symptoms cause clinically significant distress or\n     impairment in social, occupational, or other important areas of functioning.\n\nE.\t The disturbance is not attributable to the physiological effects of a substance\n     (e.g., a drug of abuse, a medication) or another medical condition\n     (e.g., hyperthyroidism).\n\nF.\t T he disturbance is not better explained by another mental disorder (e.g., anxiety or\n     worry about having panic attacks in panic disorder, negative evaluation in social\n     anxiety disorder [social phobia], contamination or other obsessions in obsessive-\n     compulsive disorder, separation from attachment figures in separation anxiety\n     disorder, reminders of traumatic events in posttraumatic stress disorder, gaining\n     weight in anorexia nervosa, physical complaints in somatic symptom disorder,\n     perceived appearance flaws in body dysmorphic disorder, having a serious illness\n     in illness anxiety disorder, or the content of delusional beliefs in schizophrenia or\n     delusional disorder).\n\nSource: Reprinted with permission from the American Psychiatric Association. Diagnostic and Statistical Manual of Mental\nDisorders.\u00a05th ed. Washington, DC: American Psychiatric Association; 2013:222.\n\nspecificity.8\u00a0Greater GAD-7 scores corre-    PANIC DISORDER\nlate with more functional impairment.8\u00a0The\nscale was developed and validated            PD is characterised by episodic, unex-\nbased on DSM-IV criteria, but it remains     pected panic attacks that occur without\nclinically useful after publication of the   a clear trigger.5\u00a0 Panic attacks are defined\nDSM-5 because the differences in GAD         by the rapid onset of intense fear (typi-\ndiagnostic criteria are minimal. The         cally peaking within about 10 minutes)\nPRO-MIS Emotional Distress \u2013 Anxiety avail-  with at least four of the physical and\nable from the American Psychiatric           psychological symptoms in the DSM-5\nAssociation at\u00a0http:\/\/www.psychiatry.org\/    diagnostic criteria\u00a0(see Table 3).5\u00a0\npractice\/dsm\/dsm5\/online-assessment-\nmeasures, are intended to aid clinical         Another requirement for the diagnosis of\nevaluation of GAD and monitor treatment      PD is that the patient worries about further\neffectiveness.                               attacks or modifies his or her behaviour in\n                                             maladaptive ways to avoid them. The\n                                             most common physical symptom\n\n                                             HANDBOOK OF GERIATRIC MEDICINE","82 NEUROPSYCHIATRIC CONDITIONS\n\nTable 2. GAD-7 screening tool                        Not at  Several  More      Nearly\n                                                     all     days     than      every\n Over the last 2 weeks, how often have you                            half the  day\n been bothered by the following problems?                             days\n\n(Use \u201c\u2713\u201d to indicate your answer)                    0       1        2         3\n                                                     0       1        2         3\n1. F eeling nervous, anxious, or on edge            0       1        2         3\n2. Not being able to stop or control worrying       0       1        2         3\n3. Worrying too much about different things         0       1        2         3\n4. \tTrouble relaxing                                0       1        2         3\n5. \tBeing so restless that it is hard to sit still  0       1        2         3\n6. Becoming easily annoyed or irritable\n7. Feeling afraid as if something awful might       =___    +___     +___      +___\n\n     happen\nTotal score_____\n\nNote:\u00a0Total score for the 7 items ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-offs for\nmild, moderate, and severe anxiety, respectively. Although designed primarily as a screening and\nseverity measure for GAD, the GAD-7 also has moderately good operating characteristics for panic\ndisorder, social anxiety disorder, and posttraumatic stress disorder. When screening for anxiety\ndisorders, a recommended cut-off for further evaluation is a score of 10 or greater.\n\nGAD: generalised anxiety disorder\n\nSource: Reprinted from Spitzer RL, Williams JB, Kroenke K, et al. Patient health questionnaire (PHQ) screeners.\u00a0http:\/\/www.\nphqscreeners.com\/overview.aspx?Screener=03_GAD-7. Accessed July 22, 2014.\n\naccompanying panic attacks is palpita-               epilepsy or transient ischaemic attacks).\ntions.9\u00a0Although unexpected panic                    Other psychiatric disorders (e.g., other\nattacks are required for the diagnosis,              anxiety disorders, major depressive disorder,\nmany patients with PD also have                      bipolar disorder); use of substances such as\nexpected panic attacks, occurring in                 caffeine, albuterol, levothyroxine, or decon-\nresponse to a known trigger.9\u00a0The severity           gestants; or substance withdrawal may also\nmeasure for panic disorder\u2013adult (http:\/\/            present with similar symptoms and should\nwww.psychiatry.org\/File\u202f%20Library\/                  be ruled out.5\nPractice\/DSM\/DSM-5\/SeverityMeasure\nForPanicDisorderAdult.pdf) is an assess-               Complicating the diagnosis of GAD and\nment scale that can complement the                   PD is that many conditions in the differen-\nclinical assessment of patients with PD.             tial diagnosis are also common co-\n                                                     morbidities. Additionally, many patients\nDIFFERENTIAL DIAGNOSIS                               with GAD or PD meet criteria for other\nAND COMORBIDITY                                      psychiatric disorders, including major\n                                                     depressive disorder and social phobia.\nWhen evaluating a patient for a sus-                 Evidence suggests that GAD and PD\npected anxiety disorder, it is important to          usually occur with at least one other\nexclude medical conditions with similar              psychiatric disorder, such as mood,\npresentations (e.g., endocrine conditions            anxiety, or substance-use disorders.10\u00a0\nsuch as hyperthyroidism, pheochromocy-\ntoma, or hyperparathyroidism; cardio-                  When anxiety disorders occur with other\npulmonary conditions such as arrhythmia              conditions, historic, physical, and labora-\nor obstructive pulmonary diseases; neuro-            tory findings may be helpful in distin-\nlogic diseases such as temporal lobe                 guishing each diagnosis and developing\n                                                     appropriate treatment plans.\n\nHANDBOOK OF GERIATRIC MEDICINE","Diagnosis and management of generalised anxiety disorder and panic disorder in adults 83\n\nTable 3. Diagnostic criteria for panic disorder                                                                                          TREATMENT APPROACHES\n\n A.\t R ecurrent unexpected panic attacks. A panic attack is an abrupt surge of intense\n      fear or intense discomfort that reaches a peak within minutes, and during which\n      time four (or more) of the following symptoms occur:\n\n      Note: The abrupt surge can occur from a calm state or an anxious state.\n\n      1.\t Palpitations, pounding heart, or accelerated heart rate.\n\n      2.\t Sweating.\n\n      3.\t Trembling or shaking.\n\n      4.\t S ensations of shortness of breath or smothering.\n\n      5.\t F eelings of choking.\n\n      6.\t C hest pain or discomfort.\n\n      7.\t Nausea or abdominal distress.\n\n      8.\t Feeling dizzy, unsteady, lightheaded, or faint.\n\n      9.\t Chills or heat sensations.\n\n      10.\t Paraesthesias (numbness or tingling sensations).\n\n      11.\t Derealisation (feelings of unreality) or depersonalisation (being detached from\n            oneself).\n\n      12.\t F ear of losing control or \u201cgoing crazy\u201d.\n\n      13.\t Fear of dying.\n\n      Note: Culture-specific symptoms (e.g., tinnitus, neck soreness, headache,\n      uncontrollable screaming or crying) may be seen. Such symptoms should not count\n      as one of the four required symptoms.\n\n B.\t At least one of the attacks has been followed by one month (or more) of one or\n      both of the following:\n\n      1.\t P ersistent concern or worry about additional panic attacks or their\n            consequences (e.g., losing control, having a heart attack, \u201cgoing crazy\u201d).\n\n      2.\t A significant maladaptive change in behaviour related to the attacks\n            (e.g., behaviours designed to avoid having panic attacks, such as avoidance\n            of exercise or unfamiliar situations).\n\n C.\t The disturbance is not attributable to the physiological effects of a substance\n      (e.g., a drug of abuse, a medication) or another medical condition\n      (e.g., hyperthyroidism, cardiopulmonary disorders).\n\n D.\t The disturbance is not better explained by another mental disorder (e.g., the panic\n      attacks do not occur only in response to feared social situations, as in social anxiety\n      disorder; in response to circumscribed phobic objects or situations, as in specific\n      phobia; in response to obsessions, as in obsessive-compulsive disorder; in response\n      to reminders of traumatic events, as in posttraumatic stress disorder; or in response\n      to separation from attachment figures, as in separation anxiety disorder).\n\nSource: Reprinted with permission from the American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.\u00a05th\ned. Washington, DC: American Psychiatric Association; 2013:208\u2013209.\n\nTREATMENT                                   section will differentiate between GAD\n                                            and PD; otherwise, treatments refer to\nSome studies evaluating anxiety treat-      anxiety-related symptoms in general.\nments assess non-specific anxiety-related\nsymptoms rather than the set of symptoms      Medication or psychotherapy is a\nthat characterise GAD or PD. When           reasonable initial treatment option for\npossible, the treatments described in this  GAD and PD.11\u00a0Some studies suggest that\n\n                                            HANDBOOK OF GERIATRIC MEDICINE","84 NEUROPSYCHIATRIC CONDITIONS\n\ncombining medication and psycho-                serotonin re-uptake inhibitors (SSRIs) are\ntherapy may be more effective for patients      generally considered first-line therapy for\nwith moderate to severe symptoms.12\u00a0The         GAD and PD.19\u201322\u00a0Tricyclic antidepressants\nNational Institute for Health and Care          (TCAs) are better studied for PD, but are\nExcellence (NICE) guidelines on GAD and         thought to be effective for both GAD and\nPD in adults are a useful review of available   PD.19,20\u00a0In the treatment of PD, TCAs are as\nevidence; however, information about            effective as SSRIs, but adverse effects may\nself-help and group therapies may have          limit the use of TCAs in some patients.23\u00a0\nless utility in the United States because of\ntheir relative lack of availability.11            Venlafaxine, extended-release, is effec-\n                                                tive and well tolerated for GAD and PD,\nEDUCATION                                       whereas duloxetine has been adequately\nCompassionate listening and education are       evaluated only for GAD.24\u00a0Azapirones,\nan important foundation in the treatment of     such as buspirone, are better than\nanxiety disorders.11\u00a0Patient education itself   placebo for GAD,25\u00a0but do not appear to\ncan help reduce anxiety, particularly in        be effective for PD.26\u00a0Mixed evidence\nPD.13\u00a0The establishment of a therapeutic alli-  suggests bupropion may have anxiogenic\nance between the patient and physician is       effects for some patients, thus warranting\nimportant to allay fears of interventions and   close monitoring if used for treatment of\nto progress toward treatment.                   comorbid depression, seasonal affective\n                                                disorder, or smoking cessation.27\n  Common lifestyle recommendations              Bupropion is not approved for the treat-\nthat may reduce anxiety-related symp-           ment of GAD or PD.\ntoms include identifying and removing\npossible triggers (e.g., caffeine, stimulants,    Medications should be titrated slowly to\nnicotine, dietary triggers, stress), and        decrease the initial activation. Because of\nimproving sleep quality\/quantity and            the typical delay in onset of action, medica-\nphysical activity.                              tions should not be considered ineffective\n                                                until they are titrated to the high end of the\n  Caffeine can trigger PD and other types       dose range and continued for at least four\nof anxiety. Those with PD may be more           weeks. Once symptoms have improved,\nsensitive to caffeine than the general          medications should be used for 12 months\npopulation because of genetic polymor-          before tapering to limit relapse.11\u00a0Some\nphisms in adenosine receptors.14 Smoking        patients will require longer treatment.\ncessation leads to improved anxiety\nscores, with relapse leading to increased         Benzodiazepines are effective in\nanxiety. Many studies show an association       reducing anxiety, but there is a dose-\nbetween disordered sleep and anxiety,           response relationship associated with\nbut causality is unclear.15\u00a0In addition to      tolerance, sedation, confusion, and\ndecreased depression and anxiety, phys-         increased mortality.28\u00a0When used in\nical activity is associated with improved       combination with antidepressants, benzo-\nphysical health, life satisfaction, cognitive   diazepines may speed recovery from\nfunctioning, and psychological wellbeing.       anxiety-related symptoms, but do not\nPhysical activity is a cost-effective           improve longer-term outcomes. The\napproach in the treatment of GAD and            higher risk of dependence and adverse\nPD.16,17\u00a0 Exercising at 60\u202f% to 90\u202f% of         outcomes complicates the use of benzo-\nmaximal heart rate for 20 minutes three         diazepines.29\u00a0NICE guidelines recommend\ntimes weekly has been shown to decrease         only short-term use during crises.11\u00a0\nanxiety16; yoga is also effective.18\n                                                  Benzodiazepines with an intermediate-\nMEDICATION                                      to-long onset of action (such as\nFirst-line therapies                            clonazepam) may have less potential for\nA number of medications are available for       abuse and less risk of rebound.30\ntreating anxiety\u00a0(see Table 4). Selective\n                                                Second-line therapies\nHANDBOOK OF GERIATRIC MEDICINE\n                                                Second-line therapies for GAD include\n                                                pregabalin and quetiapine, although","Diagnosis and management of generalised anxiety disorder and panic disorder in adults 85                                  TREATMENT APPROACHES\n\nTable 4. Medications for the treatment of generalised anxiety disorder and panic disorder\n\n First line\n Selective serotonin re-uptake inhibitors\n\n      Escitalopram\n      Fluoxetine\n      Fluvoxamine for PD\n      Paroxetine\n      Sertraline\n Serotonin-norepinephrine re-uptake inhibitors\n      Duloxetine for GAD\n      Venlafaxine, extended-release\n Azapirone\n      Buspirone for GAD\n Second line\n Tricyclic antidepressants\n      Amitriptyline\u2020\n      Imipramine (Tofranil)\u2021\n      Nortriptyline (Pamelor)\u2020\n Anti-epileptics\n      Pregabalin\u2020 for GAD\n Antipsychotics\n      Quetiapine\u2020 for GAD\n      Hydroxyzine\n Third line\n Mono-amine oxidase inhibitors\u00a7\n      Isocarboxazid\u2020\n      Phenelzine\u2020\n      Tranylcypromine\u2020\n Augmentation\n Benzodiazepines||\n      Alprazolam\u00b6\n      Clonazepam**\n      Diazepam for GAD\n      Lorazepam\u2021\n\nNote:\u00a0Medications are used for GAD and PD unless otherwise noted. They are listed from most to\nleast commonly used.\nFDA: US Food and Drug Administration; GAD: generalised anxiety disorder; NA: not available; PD:\npanic disorder.\n\u2020 Not FDA-approved for this use, although there is some evidence to support its use.\n\u2021 Not FDA-approved for PD, although there is some evidence to support its use; approved for GAD.\n\u00a7 Consideration of mono-amine oxidase inhibitors should prompt referral to psychiatry.\n|| Benzodiazepines may be used for augmentation during acute treatment. Dependence,\ntolerance, and escalating doses to get the same effect over the long term can be problematic with\nuse of benzodiazepines. Short-term prescribing with emphasis on acute management of uncon-\ntrolled anxiety is preferred. Slowly tapered dosing can prevent rebound symptoms.\n\u00b6 Short-acting benzodiazepines, such as alprazolam, are not preferred because they have a higher\nrisk of addiction and adverse effects.\n** Not FDA-approved for GAD, although there is some evidence to support its use; approved for PD.\n\n                                                                                             HANDBOOK OF GERIATRIC MEDICINE","86 NEUROPSYCHIATRIC CONDITIONS\n\nTable 5. Possible behaviour interventions for the treatment of generalised anxiety disorder,\npanic disorder, and anxiety-related symptoms33,34\n\nIntervention Comments\n\nCognitive     This intervention is useful in treating anxiety disorders. The cognitive\nbehaviour     portion assists change in thinking patterns that support fears, whereas\ntherapy*      the behaviour portion often involves training patients to relax deeply\n              and helps desensitise patients to anxiety-provoking triggers.\n\n              To be effective, therapy must be directed at the patient\u2019s specific\n              anxieties and tailored to his or her needs. There are minimal adverse\n              effects, except that behaviour desensitisation is typically associated\n              with temporary, mild increases in anxiety.33\n\nMindfulness-  This intervention promotes focused attention on the present,\nbased stress  acknowledgment of one\u2019s emotional state, and meditation for further\nreduction\u2020    stress reduction and relaxation.\n\n              Key features include moment-to-moment awareness cultivated with a\n              non-judgmental attitude, formal meditation techniques, and daily\n              practice.34\n\nNote:\u00a0Formal use of these interventions requires specialised training. In patients whose anxiety and\nimpairment are severe, referral to a trained behaviour health specialist should be considered.\n* For more information, see DiTomasso RA, Golden BA, Morris HJ, eds. Handbook of Cognitive-\nBehavioral Approaches in Primary Care.\u00a0New York, NY: Springer; 2010, and Craske MG.\nCognitive-Behavioral Therapy.\u00a0Washington, DC: American Psychological Association; 2010.\n\u2020 For more information, see Brantley J. Mindfulness-based stress reduction. In: Orsillo SM, Roemer L,\neds. Acceptance and mindfulness-based approaches to anxiety: conceptualization and treat-\nment.\u00a0New York, NY: Springer; 2005:131-145.\n\nneither has been evaluated for PD.              PSYCHOTHERAPY AND RELAXATION\nPregabalin is more effective than               THERAPIES\nplacebo, but not as effective as loraz-\nepam for GAD. Weight gain is a common           Psychotherapy includes many different\nadverse effect of pregabalin. There is          approaches, such as cognitive behaviour\nlimited evidence for the use of antipsy-        therapy (CBT) and applied relaxation\u00a0(see\nchotics to treat anxiety disorders. Although    Table 5).33,34\u00a0CBT may use applied relaxation,\nquetiapine seems to be effective for GAD,       exposure therapy, breathing, cognitive\nthe adverse effect profile is significant,      restructuring, or education. Psychotherapy\nincluding weight gain, diabetes mellitus,       is as effective as medication for GAD and\nand hyperlipidaemia.31\u00a0Hydroxyzine is           PD.11\u00a0Although existing evidence is insuffi-\nconsidered a second-line treatment for          cient to draw conclusions about many\nGAD,32\u00a0but there are minimal data for its       psychotherapeutic interventions, structured\nuse in PD. Its rapid onset can be appealing     CBT interventions have consistently proven\nfor patients needing immediate relief, and      effective for the treatment of anxiety in the\nit may be a more appropriate alternative        primary care setting.34\u201336\u00a0Psychotherapy\nif benzodiazepines are contra-indicated         may be used alone or combined with\n(e.g., in patients with a history of substance  medication as first-line treatment for\nabuse). Based on clinical experience,           PD37\u00a0and GAD,11\u00a0based on patient prefer-\ngabapentin is sometimes prescribed by           ence. Psychotherapy should be performed\npsychiatrists to treat anxiety on an            weekly for at least eight weeks to assess\nas-needed basis when benzodiazepines            its effect.\nare contra-indicated. Of note, the\nplacebo response for medications used to          Mindfulness has similar effectiveness to\ntreat GAD and PD is high.13                     traditional CBT or other behaviour thera-\n                                                pies,38\u00a0particularly mindfulness-based\n                                                stress reduction.39\u00a0A meta-analysis of 36\n\nHANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","","","","","","Osteoarthritis 111\n\nFigure 8. Diagramatic representation of factors contributing to imbalance between            TREATMENT APPROACHES\nformation and destruction of cartilage\n\nProteoglycan \u2193                                                 Proteoglycan \u2191\nCollagen \u2193                                                          Collagen \u2191\nMetalloproteinases \u2191\nMetalloproteinase inhibitor \u2193                           Metalloproteinases \u2193\n                                              Metalloproteinase inhibitor \u2191\n\nIL-1                           Chondrocyte    TGF-b\n\nensure that the same technician, exposure,    adequately, codeine-containing medica-\nposition and other factors are controlled.    tions and subsequently opioid analgesics\nThis is extremely difficult. The use of       may need to be used.14\nmagnetic resonance imaging (MRI) may\nbe useful in this kind of research, but can     The use of nonsteroidal anti-inflamma-\nprove to be extremely expensive.12            tory drugs (NSAIDs) in the treatment of OA\n                                              remains controversial. Their use is probably\n  Recent research has shown a useful          related to the analgesic properties of\nprotective effect from exercise, especially   these agents. Major side effects of therapy\nstrengthening of the quadriceps muscle        with NSAIDs include peptic ulceration,\nfor knee OA. Previously, exercise was         hypertension and increased cardiovas-\ndiscouraged because of the fear of            cular complications. A new class of\ncausing OA from overuse of the joints.        agents, known generally as COXIBS,\nHowever, in the USA, as part of the           provided superior safety for gastro-intes-\nFramingham study, long-term studies have      tinal toxicity, but have shown increased\nshown no increase in the prevalence of        incidence of hypertension, stroke and\nOA in subjects who jog several kilometres     heart attacks. These agents prevent the\nregularly. Another important preventive       production of prostaglandins by selec-\nstrategy for OA of the knee is weight         tively inhibiting the COX-2 enzyme, which\nreduction.13 Studies have shown that a five   converts arachidonic acid. This COX\nkg weight loss will lead to a 56\u202f% reduction  isomer is only active in inflammatory\nin risk of knee OA if body mass index is      conditions, so that these NSAIDs do not\ngreater than 25. There is no relationship     lower physiologically produced prosta-\nbetween obesity and OA of the hip.            glandins, which serve important\n                                              homeostatic mechanisms in the kidney,\n  Disease-modifying drugs for OA have         platelets and gastro-intestinal tract. The\nbeen elusive and cartilage repair tends to    reported increased risk of cardiovascular\nbe extremely slow or nonexistent. The use     events is most likely due to the effects of\nof dietary supplements in the form of         these drugs on thromboxane. More\nglucosamine sulphate is controversial.        recent reviews of the literature suggest\nThere is little doubt about the additional    that these dangers exist even with the\nrelief of pain provided by these supple-      conventional NSAIDs.15\nments, which need to be used at an\nadequate dose. The main objective of            Preventive treatment is generally unsat-\ntreatment, nowadays, is to provide pain       isfactory and the end result is usually joint\nrelief. This can be achieved with the use of  failure. Total hip and knee arthroplasty has\nsimple analgesics in the majority of cases.   been a major development in the rehabili-\nIf simple analgesics do not control pain      tation of patients with OA of the knee and\n\n                                                             HANDBOOK OF GERIATRIC MEDICINE","112 MUSCULOSKELETAL CONDITIONS AND PAIN\n\nhip, respectively. The waiting list at most     and most centres would encourage the\nhospitals for these procedures is in excess     prophylactic use of heparin to prevent this\nof three years and depends on the exper-        potentially fatal complication.16\ntise of the orthopaedic surgeon. The\nprosthesis, cost of theatre, anaesthesiolo-     CONCLUSION\ngist, as well as other direct costs related\nto the surgery and materials result in the      Due to the massive burden of OA on\ncost to a patient of around R120 000 in a       society, extensive research is continuing to\nprivate hospital. At Groote Schuur              develop ways to control this serious\nHospital, over 1 200 patients are currently     disease associated with ageing. Much is\nawaiting knee or hip joint replacement.         being learnt about the biochemical\nSadly, many of these remain confined to         changes accompanying OA, but the\na wheelchair due to major difficulties with     impact of these on therapy are still unclear\nwalking.                                        and experimental. Promising results are\n                                                being shown from animal experiments\n  The initial treatment is usually with simple  and some of the exciting developments\nanalgesics, predominantly paracetamol.          may be with the use of stem cells that are\nThe next step would be to use combined          programmed to mature into cartilage-\nparacetamol plus codeine. If this fails, one    producing cells (chondrocytes). The use of\nwould need to go onto tramadol or stronger      this agent in humans is likely to be some\ncodeine compounds. Intra-articular injec-       years in the future. Until then, analgesic\ntion into a single joint sometime produces      therapy and eventually joint replacement\nprolonged relief and may be repeated            surgery remain the treatment of choice for\nevery three months, especially in patients      all patients with progressive OA of the\nhaving to sit through long waiting lists for    knee and\/or hip. In many patients, the\nsurgery. Eventually, the quality of life may    pain may be unrelated to the OA demon-\nonly be improved by joint arthroplasty.         strated radiologically and it may be arising\n                                                from the non-articular structures such as\nWHEN TO REFER                                   ligaments, tendons and bursae. Occa-\n                                                sionally, the pain may be referred from\nOsteoarthritis is generally a condition         another area such as hip disease causing\ntreated in the primary health-care setting.     pain in the knee. In spite of the increased\nThe above therapeutic measures will be          knowledge about OA and the extensive\neffective in treating the majority of           research around OA, much still remains\npatients. The main indication for referral to   unknown about the disease.\na rheumatology or orthopaedic unit\nwould be for a decision regarding surgery,      REFERENCES\nor if the source of the pain is not clear. The  1.\tGabriel S, Crowson C, O'Fallon W. Costs of\ntiming of surgery is determined by the\nextent of pain and disability suffered by             osteoarthritis: estimates from a geographi-\nthe patient, rather than the extent of                cally defined population. J Rheumatol.\nchanges observed on the x-ray. There is a             1995;22(Suppl 43):23-25.\nreasonable correlation between the              2.\tVos T, Murray CJL, Barber R, et al. Glo-\nseverity of radiological change and                   bal, regional, and national incidence,\nextent of pain, but disability is not always          prevalence, and years lived with disability\nproportional to the changes seen on                   for 301 acute and chronic diseases and\nx-ray. Trochanteric bursitis, pes anserine            injuries in 188 countries, 1990-2013: a\nbursitis and De Quervain's tenosynovitis              systematic analysis for the Global Burden of\nare not uncommon in patients with                     Disease Study 2013. Lancet. 2015;386\nco-existing mild OA, and significant pain             (9995):743-800.\nrelief can be achieved from local corti-        3.\tGhosh P. Articular cartilage: what it is, why it\nsone injections in these situations. Deep             fails in osteoarthritis, and what can be done\nvenous thrombosis is more common                      about it. Arthritis Care Res 1988;1:211-221.\nfollowing lower limb surgery of this nature     4.\tMessier SP, Loesser RF, Mitchell MN, et al.\n                                                      Exercise and weight loss in obese older adults\nHANDBOOK OF GERIATRIC MEDICINE                        with knee osteoarthritis: a preliminary study. J\n                                                      Am Geriatr Soc. 2000; 48:1062-1072.","Osteoarthritis 113\n\n5.\tDequeker J, Boonen S, Aerssens J, et al.        12.\tCibere J, Sayre EC, Guermazi A, et al. Do       TREATMENT APPROACHES\n      Inverse relationship osteoarthritis-osteopo-         physical examinations predict OA progres-\n      rosis: What is the evidence? What are the            sion based on MRI? Results from the\n      consequences? Br J Rheumatol. 1996;                  Vancouver knee osteoarthritis progression\n      35:813-818.                                          study. Osteoarthritis and Cartilage.\n                                                           2011;19:S148.\n6.\tAbramson SB, Attur M. Developments in the\n      scientific understanding of osteoarthritis.    13.\tHuang MH, Chen CH, Chen TW, et al. The\n      Arthritis Res Ther. 2009;11:227.                     effects of weight reduction on the rehabili-\n                                                           tation of patients with knee osteoarthritis\n7.\tFelson DT, Anderson JJ, Naimark A, et al.             and obesity. Arthritis Care Res. 2000;\n      Obesity and knee osteoarthritis. The                 13:398-405.\n      Framingham Study. Ann Intern Med.\n      1988;109:18-24.                                14.\tChou R, Fanciullo GJ, Fine PG, et al. Clinical\n                                                           guidelines for the use of chronic opioid\n8.\tBierma-Zeinstra SM, Oster JD, Bernsen RM,              therapy in chronic noncancer pain. J Pain\n      et al. Joint space narrowing and relation-           2009;10:113-30.\n      ship with symptoms and signs in adults\n      consulting for hip pain in primary care.       15.\tAmerican College of Rheumatology Ad\n      Journal of Rheumatology. 2002;29                     Hoc Group on Use of Selective and\n      (8):1713-1718.                                       Nonselective Nonsteroidal Anti-inflam-\n                                                           matory Drugs. Recommendations for use of\n9.\tWilliams CJ, Jimenez SA. Heredity, genes              selective and nonselective nonsteroidal\n      and osteoarthritis. Rheum Dis Clin North             anti-inflammatory drugs: an American\n      Am. 1993;19:523-543.                                 College of Rheumatology white paper.\n                                                           Arthritis Rheum. 2008;59:1058-73.\n10.\tBrighton S, et al. Management of osteo\n      arthritis \u2013 clinical guideleine 2000. South    16.\tAmin AK, Clayton RA, Patton JT, et al. Total\n      African Medical Journal. 2003; 93:1012-              knee replacement in morbidly obese\n      1020.                                                patients. Results of a prospective, matched\n                                                           study. Journal of Bone and Joint Surgery \u2013\n11.\tWandel S, Juni P, Tendal B, et al. Effects of        British Volume. 2006;88(10):1321-1326.\n      glucosamine, chondroitin, or placebo in\n      patients with osteoarthritis of hip or knee:\n      network meta-analysis. BMJ. 2010; 34:c4675.\n\n                                                     HANDBOOK OF GERIATRIC MEDICINE","114 MUSCULOSKELETAL CONDITIONS AND PAIN\n\nOsteoporosis\n\nDr AJ de Weerd                                  imbalance in bone turnover \u2013 either\nMB ChB MMed (O&G)                               increased osteoclastic bone resorption,\n\uf072\t Specialist in Osteoporosis, Osteoporosis     which can be caused by reduced\nClinic, Pretoria East Hospitral, Pretoria       oestrogen levels in postmenopausal\n                                                women, or reduced osteoblasctic bone\nOsteoporosis is the most common meta-           formation, which can occur as a result of\nbolic bone disease, affecting one in two        oral glucocorticoid therapy. Bone strength\nwomen and one in five men aged older            reflects the integration of bone mass\nthan 50 years in the western world. Women       density and bone quality.3,4 Bone quality is\nhave a 50\u202f% lifetime risk at age 50 of          determined by bone geometry, turnover,\nhaving an osteoporotic fracture and a           micro-architecture, modelling and\n20\u202f% risk of having a hip fracture. The one-    remodelling, and material content (which\nyear mortality rate for hip fracture in         includes mineral, collagen, crystal struc-\nwomen is approximately 20\u202f%. The                ture and micro-damage). In patients with\naverage hospital stay for hip fracture is 25    osteoporosis, low-trauma fractures, also\ndays, 23 days for pelvic fracture. The cost     known as insufficiency fractures, occur\nof one hip fracture is approximately            most commonly in the wrist, spine and\nR120\u00a0000. The burden of cost of fractures is    hip.5 Such fractures, particularly those of\nestimated to be \u20ac31 billion in France,          the hip, cause considerable morbidity\nSpain, Sweden and the UK in 2010.               and mortality with consequent individual\n                                                and societal effects.6\nDEFINITION\n                                                The various parameters listed can be\nThe World Health Organization (WHO)             determined in vivo, using\ndefines osteoporosis as a systemic skeletal     n\t D ual-energy X-ray absorptiometry\ndisease that is characterised by low bone       n\t CT and quantitative CT\nmass and micro-architectural deteriora-         n\t Measurement of bone turnover\ntion of bone tissue, with a consequent\nincrease in bone fragility and susceptibility       markers\nto fracture which usually involves the wrist,   n\t H igh-resolution CT and high-resolution\nspine, hip, ribs, pelvis or humerus.1 In 1994\nthe WHO proposed a stratified definition of         MRI and in vitro, using nano-imaging\nosteoporosis, which was updated in 2008,            technologies (e.g., synchrotron)\nthat encompassed the concepts of both\nlow bone mass and fracture.                     Improved reporting of radiographic\n                                                features that suggest osteoporosis and the\nCAUSES                                          presence of vertebral fracture, which are\n                                                powerful predictors of future fractures,\nAccording to this classification, there are     could increase the frequency of appro-\nfour general categories: normal, low bone       priate DXA referrals. Quantitative CT\nmass (osteopenia), osteoporosis and             remains predominantly a research tool,\nsevere osteoporosis.\u00b2 In childhood, osteo-      but has advantages over DXA \u2013 allowing\nporosis can occur as a consequence of           measurement of volumetric density, sepa-\ndefective or reduced bone formation that        rate measures of cortical and trabecular\nresults in low peak bone mass. Inherited        bone density, and evaluation of bone\ndiseases, such as osteogenesis imperfect,       shape and size. High-resolution imaging,\nand acquired chronic disease that cause         using both CT and MRI, has been intro-\nimmobilisation or malnutrition can result in    duced to measure trabecular and cortical\nlow peak bone mass. In adults, osteopo-         bone microstructure. Although these\nrosis is caused by disorders that result in an  methods provide detailed insights into the\n                                                effects of disease and therapies on bone,\nHANDBOOK OF GERIATRIC MEDICINE","Osteoporosis 115\n\nthey are technically challenging and not         fracture, e.g., vertebral fractures, propen-      TREATMENT APPROACHES\nwidely available, so they are unlikely to be     sity to falls, hypovitaminosis D and so on. It\nused in clinical practice.                       furthermore ignores the dose-effect of risk\n                                                 factors such as glucocorticoid use and\nRISK FACTORS                                     cannot assess young individuals. Its major\n                                                 limitation for local application is the near\nDual-energy X-ray absorptiometry (DXA) is        total absence of South African fracture\nthe most widely available and commonly           data. To prevent anxiety with the diag-\nused method for clinical diagnosis of            nosis of osteopenia in patients at a\nosteoporosis and will remain so for the          relatively young age (<65), the FRAX\u00ae tool\nforeseeable future. The WHO 10-year              can be a significant advantage.\nfracture risk assessment tool (FRAX\u00ae)7 will\nimprove clinical use of DXA and the cost-        AN INTEGRATED APPROACH\neffectiveness of therapeutic intervention.       TO FRACTURE-RISK ASSESSMENT \u2013\nEmploying meta-analyses from 12 large            THE NOFSA MODEL 8\nprospective population studies (<60 000\nsubjects), John Kanis and his team at the        NOFSA published the following recom-\nWHO have recently identified a number of         mendations on an integrated approach\nrobust clinical risk factors (CRFs) that         to manage osteoporosis in postmeno-\nappear to predispose to fracture in most         pausal women and men over the age of\npopulations. These include:                      50 years.\nn\t A n advanced age                             n\t T reatment should be considered when\nn\t Previous fragility fracture\nn\t Family history of osteoporotic hip               a prior fragility fracture is present.\n                                                 n\t T reatment should be considered when\n    fracture\nn\t Bone-toxic drugs such as                         the DXA T-score is below -2.5 at the hip\n                                                     or spine.\n    glucocorticoids                              n\t Treatment should also be considered in\nn\t Lifestyle factors (e.g., alcohol,                patients with osteopenia (T-score\n                                                     between -1.0 and -2.5) after careful\n    smoking, physical inactivity, diet)              consideration of CRFs and BMD values.\nn\t Excessive leanness (BMI <19 kg\/m\u00b2)               Fracture risk is three- to fivefold lower in\nn\t P ropensity to falls                             patients aged 50 years compared with\nn\t T he secondary osteoporosis                      those aged 85 years. Incorporating the\n                                                     major clinical risk factors, NOFSA has\nHaving identified the major clinical risk            proposed a simple clinical algorithm\nfactors for the development of osteopo-              for the management of osteoporosis\nrosis, the WHO team proceeded to assess              and the need to intervene with potent\ntheir relative clinical importance (weight,          bone-active drugs (see Figure 1).\ninteractions) and along with femoral BMD\ncompiled the FRAX\u00ae assessment model.             Clinical risk factors:\nThe model output is the estimated 10-year        n\t Advanced age\nprobability of either a hip fracture alone or    n\t Prior fragility fracture\nthe major osteoporotic fractures (spine,         n\t Family history\nhip, wrist and humerus) combined.                n\t Alcohol\/smoking\/diet\n                                                 n\t Excessive leanness\n  The model does not signify an interven-        n\t Fall propensity\ntion threshold, but merely indicates a           n\t Secondary osteoporosis\nfracture probability. It is further suggested\nthat, in the absence of a model for a            PHARMACOLOGICAL TREATMENT\nparticular country, a surrogate country\nshould be used, based on the likelihood          Medications used to treat osteoporosis fall\nthat it is representative of the index country.  into two classes: The antiresorptive drugs\n                                                 slow the resorption of bone \u2013 an osteo-\n  Although a number of limitations of the        clastic activity, while the anabolic drugs\nFRAX\u00ae tool have been noted, i.e., models\ndo not include a number of risk factors for                     HANDBOOK OF GERIATRIC MEDICINE","116 MUSCULOSKELETAL CONDITIONS AND PAIN\n\nFigure 1. Algorithm for the management of osteoporosis in postmenopausal women and\nmen aged \u226550 years\n\n                        Women and men with CRFs        Clinical risk factors\n                        Prior osteoporotic fracture**  \u2022 Advanced age\n                                                       \u2022 Prior fragility fracture\n                                                       \u2022 Family history\n                                                       \u2022 Alcohol\/smoking\/diet\n\nYes*                                         No \u2022 Excessive leanness\n           \u22642,5                                                       \u2022 Fall propensity\n\n                                Measure BMD***         \u2022 Secondary osteoporoses\n\n                                             T-score   Consider\n\n                                <-1.0 to >-2.5         FRAX                     \u2265-1.0\n\n                 >75yr                65-75 yr         <65 yr\n                                          +\n\n                                      \u22652 CRFs\n\n                                Yes No\n\n                                             Individualised assessment\n                                                    of CRFs + BMD\n\n                                             Yes ? No\n\n                                                BTMs         Reassess\n                                                             in 24\/12\n\nConsider specific treament                             Lifestyle measures only\n\n* Also measure BMO; ** Fracture of hip, spine, wrist, pelvis or humerus; *** Hip, spine, \u00b1 wrist\n\nstimulate new bone formation \u2013 an osteo-     DUAL ACTION\nblastic activity.                            Strontium ranelate is a dual-action drug.\n\nANTIRESORPTIVES                              SELECTION OF DRUGS\nThe largest group of drugs used to slow the\nresorption of bone are the bisphospho-       The reality is that all drugs halve the frac-\nnates and the best known are alen-           ture risk and data differ depending on the\ndronate, risedronate, ibandronate and        design of the drug study and the fracture\nzoledronic acid. Other drugs slowing         risk in the population studied.\nresorption are oestrogens and the selective\noestrogen receptor modulator, raloxifene.      In most cases, the side effects will force\n                                             the clinician to individualise treatment.\nANABOLICS\nThe main drugs presently available are the     The epithelium of the oesophagus is very\nparathyroid hormone (PTH 1-84) or its        sensitive to bisphosphonates and patients\nN-terminal fragment (PTH 1-34), called       with reflux disease and difficulty in swal-\nteriparatide, which are given daily by       lowing cannot use oral bisphosphonates.\nsubcutaneous injection.                      The drug cannot be broken into smaller\n                                             pieces.\n\n                                               Osteonecrosis of the jaw (ONJ) was first\n                                             published in 2004, referring mostly to use in\n\nHANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","","","","","","Acute lung infections in the elderly 141\n\nantimicrobials is prohibitively high, with       old man\u2019s friend and considered it as almost    TREATMENT APPROACHES\nlimited promise of return on investment,         a natural form of death. The diagnosis of\ntherefore most life-science companies            pneumonia must only be applied to infec-\nnow focus on other areas for drug devel-         tion of the distal respiratory bronchioles and\nopment. Antibiotics should not be used in        alveoli. Not all respiratory infections should\npatients with viral infections and should be     be labelled pneumonia as their manage-\nused with great circumspection when indi-        ment and prognoses may differ.\ncated; prescribing the correct product for\nthe correct patient. (Comorbid conditions,         A community study from Nottingham in\nage, demographics and season should              the UK showed that the average general\ninfluence choice when prescribing empiri-        practitioner will see eight to 10 cases of\ncally or when culture results are available.)    pneumonia a year. 75\u202f% of them can be\n                                                 managed at home. HIV infection has,\n  The use of vaccination must be                 however, changed the picture in South\npromoted. Fortunately, we can now                Africa in that younger adults now form\npredict the expected viral causes of influ-      part of the pneumonia group. For\nenza and therefore should have the               example, Johannesburg-based pulmo-\ncorrect vaccine ready. Antibacterial             nologist Prof Charles Feldman, in the major\nvaccination is also available to reduce          academic hospital where he practises,\npneumococcal respiratory infections.             now cares mostly for HIV-infected patients\n                                                 with pneumonia. The scenario would vary,\n  In the meantime, diagnostic tools such as      depending on where a doctor works and\nthe fibre-optic bronchoscope, CT-scan            if there are old age homes in the catch-\nand improved lung function-testing               ment area of the practice.\nmethods have also been developed, as\nwell as microbiological testing methods, to      DIAGNOSIS\ngive medical professionals quicker answers.\n                                                 The onset of pneumonia is usually fairly\n  This then is the scenario that has devel-      sudden, with the hallmark features of\noped during the lifetime of the elderly          infection, such as fever, a faster respiratory\npatient to whom we now attend. We should         rate and a raised pulse rate which in the\nalso keep in mind that the ethical considera-    elderly may be masked by medication\ntions of our profession have developed to a      such as \u03b2-blockers. If the signs are bilateral\npoint where they are not adequately              and in the lower lobes of the lung,\ncovered by the Hippocratic Oath. The             concomitant cardiac failure should be\nfamily doctor doing house calls at all hours is  ruled out. Stony dullness on percussion\nan increasingly rare occurrence. Medical         may indicate a complication or cardiac\nschemes often determine funded therapy           failure. If wheezing is present, the bronchi\nand doctors have to, for example, explain        are also affected and the emphasis\nthe reasons for a patient being admitted to      should be on bronchopneumonia or\nhospital. Cost control is stressed and the       bronchitis. Beware of the silent lung in a\nmeasurement of patient-reported                  short-of-breath patient with a fever when\noutcomes, as well as of doctor- and              bronchiolitis may be present.\nhospital-specific clinical outcomes, has\nbecome increasingly important.                     If possible, an X-ray of the chest should\n                                                 be done to confirm the diagnosis and the\n  In considering the elderly patient with        extent of the consolidation, the presence\nlung disease, we must remember that it is        of cavitations, pleural effusion and an\nnot only the lungs that have aged but the        enlarged cardiac shadow. If the patient is\nentire body \u2013 however, not all organs lose       severely ill and already in respiratory\ntheir functional reserve at the same rate.       failure, it must be remembered that earlier\n                                                 antibiotic use will improve the prognosis:\nCOMMUNITY-ACQUIRED                               Do not wait for an X-ray to be done; start\nPNEUMONIA                                        definitive treatment in the severely ill\n                                                 elderly. In order to evaluate the severity of\nThe Canadian physician, Sir William Osler\n(1849-1920) described pneumonia as the                          HANDBOOK OF GERIATRIC MEDICINE","142 PULMONARY CONDITIONS\n\nthe illness, the patient must have his or her     breaths\/min, B \u2013 blood pressure systolic\nblood urea done. The white cell count as          <90 mm Hg and\/or diastolic <60 mm Hg,\nwell as the serum albumin can be taken at         65 \u2013 age over 65 years.\nthe same time. Oximetry should be widely\navailable and gives a good idea of blood            Score one point for each parameter.\noxygenation and whether there is respira-         Patients with 0 or 1 can be managed at\ntory failure (<90\u202f%). The clinical sign of        home. A score of 2 warrants admission to a\ncyanosis is known to be difficult to assess       hospital for observation. A patient with\nand the accuracy varies amongst                   scores of 3 and higher should be admitted\ndoctors. Arterial blood gasses will also          to high care; those with scores of 4-5 may\nsupport the diagnosis of respiratory failure      need intensive care with possible ventilator\n(PaO2 <60 mm Hg or <8 kPa) and of                 support. Mortality prediction: score 0 =\nexhaustion\/hypoventilation (CO2 rising).          0.7\u202f%; score 1 = 3.2\u202f%; score 2 = 3\u202f%; score\nUse the CURB-65 scoring system to assess          3 = 17\u202f%; score 4 = 41.5\u202f% and score\nprognosis (mortality).                            5 = 57\u202f%. Patients with a comorbid diagnosis,\n                                                  such as ischaemic heart disease, diabetes,\nDIAGNOSING SPECIFIC                               previous stroke disease and Parkinson\u2019s\nAETIOLOGICAL ORGANISMS                            disease, may need earlier admission.\n\nIn the past, the clinical picture was unreli-     TREATMENT\nable for a specific aetiological diagnosis.\nThe use of sputum cultures, even with             Caring for the patient with pneumonia\ncriteria such as sputum cell-type and             does not mean that we should stop all\n-count with oropharyngeal swabs, gave a           other treatment for conditions such as\ndiagnosis in only 38\u202f% of cases: viruses in       diabetes, cardiac failure, ischaemic heart\n23\u202f%, bacteria in 11\u202f% and a combination          disease, Parkinson\u2019s disease and rheu-\nin 3\u202f%; tuberculosis or fungus infections in      matic conditions.\n1\u202f%.3 We know that in the 1918 flu epide-\nmic, a secondary bacterial infection                The majority of bacterial community-\ncomplicated the initial viral infection. With     acquired pneumonias would be Strep-\nmodern methods, such as polymerase                tococcus pneumoniae and Haemophilus\nchain reaction, early specific diagnosis          influenzae. Since elderly patients often\ncan be made even in the prodromal                 reside in care facilities, a health care-\nphase of the infection. This is, however, still   related pneumonia should be consi-\nvery expensive.                                   dered.4 In those living in old-age homes,\n                                                  Staphylococcus aureus, Klebsiella pneu-\nHOSPITALISATION                                   moniae and Enterobacter should be\n                                                  suspected. Viral infections are also easily\nIn order to improve the prognosis of seri-        spread in old age homes. In the younger\nously ill patients, it is important to carefully  patient, HIV may be the underlying cause,\nselect those who must be admitted to              but it should be remembered that elderly\nhospital. In frail, elderly patients, however,    patients on modern biological treatment\nthere may be considerations other than            for, e.g., rheumatic disease, are also at\nthe pneumonia itself that warrant atten-          greater risk for infections.5 With the above\ntion, such as their social support system.        in mind, patients with bacterial CAP\nGiving a prescription to a frail, elderly         should be started on an antibiotic such as\npatient who lives on his or her own is unac-      ampicillin 0.5 g every 6 hours or amoxicillin\nceptable. For example, elderly people             1-2 g 8-hourly, orally. In rural areas where\nliving alone often have pets, which may           resistance may be less of a problem,\nbe the reason why some resist admission.          penicillin G 1.2 g 6-hourly IM can be used.\n                                                  In hospital, the antibiotics can be given\n  To assist in making an informed decision        parenterally. It must be kept in mind that\nas to whether to admit or not, the CURB-65        Staphylococcus aureus and particularly\nseverity score is helpful: C - confusion, U \u2013     methicillin-resistant (MRSA) bacteria\nurea >7 mmol\/l, R \u2013 respiratory rate >30          seldom cause community-acquired\n\nHANDBOOK OF GERIATRIC MEDICINE","Acute lung infections in the elderly 143\n\npneumonia. In the study by Self in the USA         immobility. This causes prolonged rehabili-    TREATMENT APPROACHES\n(n = 2259), 1.6\u202f% patients had staphylo-           tation in the elderly.\ncoccal community-acquired pneumonia;\nof these 0.7\u202f% was MRSA. The almost                  In the past, corticosteroid therapy in CAP\nroutine use of anti-MRSA antibiotics in            was frowned upon, but several recent\nhospital is not indicated.6                        studies have shown that prednisone at a\n                                                   dosage of between 20 and 60 mg a day\n  Where atypical infections are consid-            for seven days reduces morbidity and\nered, aminopenicillin should be combined           complications in patients admitted to\nwith erythromycin 500 mg 6-hourly or               hospital. This may be because of the\nclarithromycin 500 mg 12-hourly or azithro-        reduction of the cytokine and inflamma-\nmycin 500 mg daily.                                tory responses even in viral infections.8\n\n  Patients should respond to the above               Discharge arrangements should start on\ntherapy within 24 to 72 hours, but resolu-         admission of the patient to hospital.\ntion of the clinical signs in the elderly may      Patients are now discharged earlier\nbe slower. Antibiotic therapy must be              because of the high cost of hospitalisa-\ncontinued for at least five days in the usual      tion. Supportive care, including meals,\ninfections.7 Should the patient not respond        should be arranged during the recupera-\nto treatment, hospital admission should be         tion phase. Social workers and\nreconsidered. The reason for the lack of           home-based carers are strongly advised\nimprovement could be bacterial resist-             for selected patients.\nance, such as in a S. aureus infection;\ninfection with an unusual pathogen such              Prevention is better than cure. Although\nas Legionella, Mycoplasma pneumoniae,              elderly people who are well-nourished\nChlamydia pneumoniae, or Pneumocystis              and fit may have a better chance of\njirovecii; or tuberculosis. In patients with a     survival, they will still be exposed to\nneuromuscular disease such as Parkinson\u2019s          epidemic viral infections. The only mean-\ndisease, or who have suffered a stroke,            ingful preventive measure will be\naspiration with anaerobic organisms                vaccination against the expected influ-\nshould be considered and treatment with            enza virus infections and the pneu-\namoxycillin-clavulanate (co-amoxyclav),            mococcal bacterial infections. The annual\nwith or without metronidazole, started. A          uptake of influenza vaccination is still very\nnon-infective illness, such as pulmonary           low, even in the USA.9 Work done in China\nembolism, sarcoidosis or underlying carci-         with extremely high numbers of patients\nnoma, may be causally related. Com-                and controls has shown that side effects\nplications such as empyema would also              were minimal. In those elderly people with\nnot respond as expected.                           a decreased and slower immune\n                                                   response, a booster vaccination should\n  (The above advice is as per the article          be considered. Older patients are to be\nentitled \u201cThe management of community              given a polyvalent pneumococcal\nacquired pneumonia in adults\u201d, published           vaccine, PPSV23, when started on biolog-\nin the SAMJ of December 2007 [under                ical treatment for auto-immune diseases.10\nrevision]. It is also consistent with the British  The 13 valent pneumococcal vaccine is\nguidelines published in the BNF, number            given on a separate occasion. This should\n70, in September 2015 to March 2016. The           be repeated every four years. In spite of\nPocket Guide to Antibiotic Prescribing for         the promises of the vitamin industry in the\nAdults in South Africa, published on behalf        lay press, it is hard to substantiate them\nof the South African Antibiotic Stewardship        with well-controlled double-blind studies.\nProgramme in 2015, can be most helpful.)\n                                                     Coughing bouts in the patient with\n  Bed rest should be kept to a minimum as          pneumonia can be very tiring and prevent\nthe patient\u2019s recovery may be compli-              night-time sleep. Codeine containing\ncated not only by pressure ulcers, but also        cough mixture given at night may help the\nby muscle atrophy which starts within              patient to rest better, however, constipa-\nhours and causes weakness and                      tion must be prevented.\n\n                                                                  HANDBOOK OF GERIATRIC MEDICINE","144 PULMONARY CONDITIONS\n\nDuring the acute phase, physiotherapy          ACUTE BRONCHITIS\nmay only prolong this phase, as was            AND INFLUENZA\nshown in a Swedish paper. When the\nacute phase has passed, the temperature        Wintertime is the season for acute bron-\nis normalising and the crackles are            chitis. It is usually caused by viral infections\nsubsiding, physiotherapy will benefit the      such influenza A or B viruses, adenoviruses\npatient and aid in his or her mobility.        or rhinoviruses in adults. In the elderly,\n                                               respiratory syncytial and parainfluenza\n  Routine, empathetic nursing care is          viruses should also be added. Secondary\nexpected and insisted upon for elderly         bacterial infections may occur. Vac-\npatients. Initially, they may need assis-      cination is only against the influenza A and\ntance with the eating of small, regular        B infections seen in epidemics; other\nmeals and drinking of sufficient fluids. In    respiratory viruses may still be the cause of\nthe severely demented patient, tube-           the same symptoms.\nfeeding should be resisted.\n                                                 In view of the viral aetiology, antibiotics\n  Special care to prevent pressure ulcers      should not be given in the otherwise\nmust be given and the caring doctor will       healthy elderly patient. Yellow, purulent\ninspect pressure areas daily: heels and toes,  sputum does not signify a bacterial\nthe sacral region and the occipital scalp.     infection.13\n\nPROGNOSIS                                        The American College of Physicians,\n                                               amongst others, has been educating\nPneumonia is still among the more              doctors for the past 15 years in the correct\ncommon causes of death in the elderly.         use of antibiotic therapy. In a study of\nBetween 6 and 24\u202f% of hospitalised             3\u2002 153 visits to physicians\u2019 offices and\npatients may still die.                        hospital outpatients for acute bronchitis\n                                               without underlying lung diseases, the use of\n  A study of three million Medicare benefi-    antibiotic-prescribing for adults with acute\nciaries in the USA demonstrated that in the    bronchitis actually increased to 40\u202f%.14\nyear following hospital admission for\npneumonia, 31\u202f% of these patients died.          When antibiotics are not prescribed, we\nThey are also at a six- to 11-time greater     must not ignore the patient. Cough\nrisk for readmission than the elderly in the   suppressants, such as a codeine-\ngeneral population.11                          containing cough mixture or pholcodine,\n                                               is indicated at night. It is amazing how well\nCARING FOR THE CARE-GIVERS                     the capsaicin-containing lozenges\n                                               Fisherman\u2019s Friend work during the day. A\nWe tend to forget the care-givers for the      \u03b2-receptor stimulant inhaler not only\nfrail elderly. This may be a family member     relieves bronchospasm, but also stimulates\nor spouse who has been carrying the            cilial function.15 The patient must be\nburden for years.                              warned that the cough may last for as\n                                               long as six weeks.\n  In a Canadian study on care-givers,\npartly based on a questionnaire given out        Exercise such as jogging may increase\nseven days after the discharge of patients     the respiratory rate and depth of\nwho had been admitted to hospital for          breathing. The increase of airflow leads to\nintensive care and ventilator therapy,         evaporation of fluid in the bronchi and\n70\u202f% of care-givers were female, 61\u202f% a        therefore has a cooling effect. This may\nspouse, and 66\u202f% had depression.               cause bronchospasm in the asthmatic\n                                               and stimulate the coughing reflex. The\n  After one year, 55\u202f% were still consid-      elderly may find that staying in a tempera-\nered depressive. It was the younger            ture-controlled atmosphere will reduce\ncare-givers with the least social support      the tendency to cough.\nwho suffered the most.12\n                                                 The use of antiviral medication such\n  Burnout in the care-giver is a reason for    as oseltamivir in patients with influenza\nabuse of the elderly. Attention to this        has been shown to be effective in\ncommon problem should help to improve\nlong-term care for the elderly.\n\nHANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","","","","","","","","Photo-ageing lesions including solar keratosis\/actinic keratosis 171\n\n      (\u201cactinic keratosis\u201d).\u00a0J Am Acad Dermatol.            cancerization. A randomized placebo-              TREATMENT APPROACHES\n      2000;42(1, pt 2):11-17.                               controlled study. Br J Dermatol. 2010; 162:\n5.\tMarks \u00a0R, Jolley \u00a0D, Dorevitch \u00a0AP, et al. \u00a0The\n      incidence of non-melanocytic skin cancers             171-175.\n      in an Australian population: results of a       17.\tBagazgoitia L, Cuevas Santos J, Juarranz A,\n      five-year prospective study.\u00a0Med J Aust.\n      1989;150(9):475-478.                                  et al. Photodynamic therapy reduces the\n6.\tMarks \u00a0R, Rennie \u00a0G, Selwood \u00a0TS. \u00a0Malignant\n      transformation of solar keratoses to squa-            histologic features of actinic damage and\n      mous cell carcinoma.\u00a0Lancet. 1988;1(8589):\n      795-797.                                              the \nexpression of early oncogenic markers.\n7.\tPatel G, Armstrong A, Eisen D. Efficacy of             Br J Dermatol. 2011;165:144-145.\n      photodynamic therapy vs other interven-         18.\tSzeimies RM, Torezan L, Niwa A, et al.\n      tions in randomized clinical trials for the           Clinical, histopathological and immunohis-\n      treatment of actinic keratoses. A system-             tochemical assessment of human skin field\n      atic review and meta-analysis. JAMA                   cancerization before and after photody-\n      Dermatol. 2014;150(12):1281-1288.                     namic therapy. Br J Dermatol. 2012;167:\n8.\tRedaelli A, Braccini F. Facial Ageing.                 150-159.\n      Oeofirenze. 2012. P44- 60.                      19.\tWeiss RA, Weiss MA, Geronimus RG, et al. A\n9.\tPuizina Ivic N. Skin Ageing. Acta Derma-               novel non thermal non-ablative full panel\n      tovan APA 2008; 17:2:47-54.                           LED photomodulation device for reversal of\n10.\tDohil MA. Efficacy, safety, and tolerability          photo-ageing: digital and clinical results in\n      of 4\u202f% 5-fluorouracil cream in a novel                various skin types. J Drugs Dermatol. 2004,\n      patented aqueous cream containing                     3(6):605-10.\n      peanut oil once daily compared with 5\u202f%         20.\tGeronimus R, Weiss RA, Weiss MA, et al.\n      5-fluorouracil cream twice daily: meeting             Non-ablative LED photomodulation-light\n      the challenge in the treatment of actinic             activated fibroblast clinical trial. Lasers Surg\n      keratosis. J Drugs Dermatol. 2016 Oct                 Med. 2003, 25:22.\n      1;15(10)1218-1224, MA Dohil.                    21.\tBoehncke WH, Sterry W, Kaufmann R.\n11.\tRossi, S, ed. (2013). Australian Medicines            Treatment of psoriasis by topical photody-\n      Handbook (2013 ed.). Adelaide: The                    namic therapy with polychromatic light.\n      Australian Medicines Handbook Unit Trust.             Lancet. Mar 26 1994;343(8900):801.\n12.\tKrawtchenko N, et al. Br J Dermatol.            22.\tBissonnette R, Lui H. Current status of photo-\n      2007;157(Suppl.2):34-40.                              dynamic therapy in dermatology.\n13.\tKalka K, Merk H, Mukhtar H. Photodynamic              Dermatol Clin. Jul 1997;15(3):507-19.\n      therapy in dermatology. J Am Acad               23.\tUebelhoer NS, Dover JS. Photodynamic\n      Dermatol. 2000 Mar;42(3):389-413; quiz 414-6.         therapy for cosmetic applications.\n14.\tMorton CA, McKenna KE, Rhodes LE.                     Dermatol Ther. May-Jun 2005;18(3):242-52.\n      Guidelines for topical photodynamic             24.\tGlogau RG. Chemical peeling and ageing\n      therapy: update. Br J Dermatol. Dec                   skin. J Geriatr Dematol. 1994;2:30-35.\n      2008;159(6):1245-66.                            25.\tKokoska MS, Thomas JR. Anatomy and\n15.\tBraathen L, Morton C, Basset-Seguin N, et             pathophysiology of facial ageing. Facial\n      al. Photodynamic therapy for skin field               Plast Surg Clin North Am. 2001;9:179-187.\n      cancerization: an international consensus.      26.\tChemical peel patient education informa-\n      International Society for Photodynamic                tion. ASAPS information website. Updated\n      Therapy in Dermatology. J Eur Acad                    2007.\n      Derma. 2012; 26: 1063-1066.                     27.\tManstein D, Herron GS, Sink RK, et al.\n16.\tApalla Z, Sotiriou E, Chovarda E, et al. Skin         Fractional photothermolysis: a new\n      cancer: preventive photodynamic the-                  concept for cutaneous remodeling using\n      rapy in patients with face and scalp                  microscopic patterns of thermal injury.\n                                                            Lasers Surg Med. 2004;34(5):426-38.\n                                                      28.\tGold MH. Fractional technology: a review\n                                                            and clinical approaches. J Drugs Dermatol.\n\n                                                            2007;6(8):849-852.\n\n                                                      29.\tGold MH. Update on fractional laser tech-\n                                                            nology. J Clin Aesthet Dermatol. 2010\n\n                                                            Jan;3(1):42\u201350.\n\n                                                      HANDBOOK OF GERIATRIC MEDICINE","172 DERMATOLOGICAL AND AESTHETIC CONDITIONS\n\nVaricose veins\n\nDr N le Grange                                External to the fascia and muscles, superfi-\nMBChB (Stell)                                 cial veins serve primarily as reservoirs with\n\uf072\t Aesthetics Centre, Tyger Waterfront,       limited transport ability.\nBellville\n                                              ANATOMY\nThe World Health Organization defines\nvaricose veins as \"saccular dilatation of     The superficial veins of the lower limbs\nveins which are often tortuous\".1             terminate in the two saphenous veins,\n                                              which drain most of the blood from the\n  The tortuous appearance is termed           superficial fascia. The great (also referred\n\"varicose\", derived from the Greek term for   to as the long) saphenous vein (GSV) is the\n\"grape-like\".                                 longest vein in the body. The GSV begins\n                                              at the medial end of the dorsal venous\n  Varicose veins are part of the spectrum     arch on the foot and passes anterior to\nof chronic venous diseases and include        the medial maleolus of the tibia. It then\nspider telangiectasias, reticular veins, and  ascends obliquely across the inferior-third\ntrue varicosities. Varicose veins alone,      of the tibia towards the medial aspect of\nwithout more advanced signs of chronic        the knee. Here it lies superficial to the\nvenous insufficiency, may also result in      medial epicondyle, approximately 10 cm\nimportant reductions in quality of life.2     posterior to the medial border of the\n                                              patella. From here, it runs to the anterior\n  Patients tend to seek therapy for telangi-  midline of the thigh and the saphenous\nectasias or varicose veins principally        opening in the deep fascia. The GSV\nbecause of their unsightly appearance.        perforates the sieve-like cribiform-fascia\n                                              and femoral-sheath forming part of the\nEPIDEMIOLOGY                                  deep fascia of the thigh and ends in the\n                                              femoral vein. The GSV anastomoses freely\nIt has generally been estimated that vari-    with the small saphenous vein.\ncose veins affect 25 to 33\u202f% of people in\nWestern countries, with an increase in        PERFORATING VEINS\nfrequency with age.3 A study conducted in     Perforating veins connect the deep veins\nLondon of people aged 35 to 70 years4         to the superficial veins. Incompetent perfo-\nconcluded that the prevalence of varicose     rators transmit high intravascular pressure\nveins in men and women was 17\u202f% and 31\u202f%      directly to their tributaries. The average\nrespectively. Over 80\u202f% of the total popula-  number of perforating veins per leg is\ntion had reticular varicosities or            found to be between 155 and 64. They\ntelangiectasia. There are few studies on the  usually contain one to three one-way\nincidence of varicose veins; however, the     valves, depending on their length.\nFramingham5 study found that the two-year     Normally perforating veins have thin walls\nincidence of varicose veins was 39.4\/1\u00a0000    varying in diameter from approximately\nfor men and 51.9\/1 000 for women.             1-2\u00a0mm. When incompetent though, perfo-\n                                              rating veins become thick-walled and may\nPATHOPHYSIOLOGY                               reach a diameter of 5 mm or more.6\n\nAlthough all veins have a similar structure,    There are one or two relatively constant\nthe particular functions of the venous        perforating veins in the thigh associated\nsystem of the leg are imposed by their        with the medial intramuscular septum\nsurroundings. When covered by muscles         known as Hunterian or Dods' perforating\nand fascia, the deep veins serve as a         veins. These connect the GSV to the\ntransport system. Depending on the            femoral vein in the mid-medial thigh and\ntension of peri-venous tissues, deep veins\nmay either draw blood from the superficial\nveins or pump blood towards the heart.\n\nHANDBOOK OF GERIATRIC MEDICINE","Varicose veins 173\n\nthe mid-lower third of the thigh.              n\t L eg heaviness                               TREATMENT APPROACHES\nIncompetence of the Hunterian perforator       n\t Exercise intolerance\nis a common cause for medial thigh vari-       n\t P ain or tenderness along the course of\ncose veins, especially in places with\ncompetent sapheno-femoral junctions.               a vein\n                                               n\t P ruritus\n  Another common perforator is Boyd's          n\t Burning sensations\nperforating vein, also called a Boyd's         n\t Restless legs\nperforator. This usually appears 10 cm         n\t N ight cramps\nbelow the knee joint on the medial aspect      n\t O edema\nof the lower limbs.                            n\t S kin changes\n                                               n\t Paraesthesias\n  Another group of perforating veins is\nlocated on the medial border of the lower      The symptoms of varicose veins are often\nleg. They usually occur in approximately       disproportionate to the amount of factual\n6\u00a0cm-10 cm, 13 cm-15 cm, 18 cm-20 cm           pathological change. Often, most\nand 24 cm-25 cm above the sole of the          patients do not realise how good their legs\nfoot. This group is referred to as the         can feel until after treatment of these\nCockett's perforators. They connect the        affected veins by either compression\nposterior arch vein with the posterior tibial  sclerotherapy or by wearing lightweight,\nveins, but do not drain directly into the      graduated compression stockings.\nsmall saphenous vein.6\n                                               SIGNS OF VARICOSE VEIN DISEASE\nLESSER SAPHENOUS VEINS\nThe small saphenous vein is also known as      It is estimated that between 17-50\u202f% of\nthe lesser saphenous vein (LSV). It is         people with varicose veins have cuta-\nformed by the union of veins rising from       neous findings. There is a strong association\nthe lateral part of the dorsal venous arch.    between the severity of clinical signs and\nThe LSV passes along the lateral side of the   superficial venous incompetence. Signs of\nfoot with the sural nerve posterior to the     venous stasis disease include:\nlateral maleolus and ascends along the         n\t A nkle oedema\nlateral side of the Achilles tendon. The       n\t Dilated veins and venules\nsmall saphenous vein passes through the        n\t T elangiectasias\npopliteal-fossa where it perforates the        n\t Corona phlebectasia\ndeep popliteal-fascia and ends in the          n\t Pigmentation\npopliteal vein. The LSV has a thick wall and   n\t Venous dermatitis\nusually measures approximately 3 mm in         n\t Atrophie blanche\ndiameter when normal.6 The small saphe-\nnous vein often receives substantial           CLINICAL MANAGEMENT\ntributaries from the medial aspect of the\nankle, thereby communicating with the          As with any medical procedure, a thor-\nmedial ankle perforators.                      ough examination and treatment\n                                               planning is essential to achieve success.\nOTHER SUPERFICIAL VEINS\nThe superficial collateral or communi-           The presence of bulging varicosities and\ncating venous network consists of many         chronic venous insufficiency are usually\nlongitudinally-, transversally- and            readily apparent. In patients with only\nobliquely-oriented veins. These veins are      telangiectasias of the legs and no\nnormally of low diameter, but when vari-       dilated veins, most doctors would agree\ncose can dilate to more than one cm.           that further non-invasive testing is\n                                               unnecessary.\nSYMPTOMATOLOGY\n                                               MEDICAL HISTORY\nCommon chronic symptoms of varicose            As with most other patients, it is important to\nveins include the following:7                  start by taking a good medical history,\n                                               including a family history of varicose vein\n\n                                                              HANDBOOK OF GERIATRIC MEDICINE","174 DERMATOLOGICAL AND AESTHETIC CONDITIONS\n\ndisease. One particular gene, FOXC2,           an incompetent deep and perforator\nlocated on chromosome 16, has been linked      system is present. Superficial venous incom-\nto lower-extremity venous valve failure.8      petence is present if superficial varicose\n                                               veins fill rapidly on tourniquet release.9\n  Take note of the time and age of onset. If\nsymptoms of varicose vein disease              NON-INVASIVE DIAGNOSTIC\nbecome worse after a period of immobili-       TECHNIQUES\nsation such as when travelling or after an     The two most popular instruments used\noperation, it may be indicative of an          will be the Doppler ultrasound and the\nunderlying deep venous thrombosis. The         duplex scanner. If the cause of varicose\nrapid onset or a progressive increase in the   veins is not clear from the clinical exami-\nsize or recent onset of oedema may show        nation or if an intervention is being\nan abdominal or pelvic tumor, for example.     considered, colour duplex scanning to\n                                               determine superficial and deep venous\n  Any prior treatment for varicose vein        reflux should be performed. Venous reflux\ndisease as well as the patient's response to   is defined as retrograde flow of >0.5\nthe different treatment modalities should      seconds in duration after distal manual\nbe noted. Any complications experienced        augmentation. Venous ultrasonography\nshould be discussed, a history of prior        can also detect deep or superficial\nhyperpigmentation, or poor response to a       venous thrombosis. If obstruction or\nparticular sclerosing agent may support a      extrinsic compression of iliac venous\nvariety of changes in treatment protocol.      segments or the inferior vena cava is\n                                               suspected, additional imaging such as\n  Symptoms and the severity thereof            computed tomography, magnetic reso-\nshould also be discussed; however, it is       nance, or invasive venography may\nimportant to note that the symptoms do         be indicated.\nnot necessarily correlate with the size or\nseverity of varicose veins present.            TREATMENT\n\n  Complications such as ulceration and         Selection of therapy for varicose veins\nhaemorrhaging should also be discussed.        should take into account symptoms, loca-\n                                               tion, severity, and cause. In addition to\nPHYSICAL EXAMINATION                           symptoms refractory to non-invasive\nUsing no special equipment, one can            measures and cosmetic concerns, recur-\nobtain a degree of information regarding       rent varicose vein haemorrhage and\noverall venous flow from the leg, signs of     superficial thrombophlebitis are indica-\nvalvular insufficiency, the presence of        tions for invasive vein therapy. Invasive\nprimary vs secondary varicose veins and        vein therapies such as sclerotherapy,\nthe presence of possible deep vein throm-      surgery, or endovenous ablation are\nbosis. It is important to view the entire leg  contra-indicated in pregnancy, acute\nand not to confine examination simply to       venous thrombo-embolism, and periph-\nthe area the patient feels is abnormal. For    eral artery disease (ankle:brachial\nthe same reason, ensure that both legs         index <0.9).\nare examined.\n                                               LIFESTYLE MODIFICATION\n  Examination techniques include the           Lifestyle modification is crucial to ensure a\ncough test, the percussion test with the       treatment response that is as complete\nBrody-Trendelenburg test the most helpful      and durable as possible. Because vari-\nand important. The Brody-Trendelenburg         cose veins are associated with obesity,\ntest can help distinguish between superfi-     weight loss is an important step in reducing\ncial venous and deep venous insufficiency      progression and preventing recurrence.\nand is performed with the patient recum-       Regular physical activity such as walking\nbent, the leg elevated to 45\u00ba, and a           and foot flexion exercises may improve\ntourniquet applied to the mid-thigh after\nthe veins have been completely drained.\nOn standing, if venous refill distal to the\ntourniquet occurs in less than 30 seconds,\n\nHANDBOOK OF GERIATRIC MEDICINE","Varicose veins 175\n\ncalf-muscle pump function. Elevation of        chestnut extract had a greater reduction        TREATMENT APPROACHES\nthe feet to at least heart level for 30        in their lower leg volume compared with\nminutes at least four times a day and          placebo after 12 weeks of therapy. The\navoidance of prolonged standing and            horse chestnut extract was well tolerated\nsitting, decompress lower extremity veins      and no adverse events were noted,\nand improve symptoms. Smoking cessa-           although gastro-intestinal irritation has\ntion should be emphasised in patients with     been reported.\nvaricose veins.\n                                               SURGICAL TREATMENT\nCOMPRESSION THERAPY                            Varicosities in branches of the major\nCompression stockings are frequently           superficial veins can be treated using stab\nprescribed as the first step in varicose vein  or micro-incision phlebectomy, which\nmanagement and are effective for treat-        requires only local tumescent anaesthesia\nment of discomfort and oedema.1                and leaves minimal scars. These microsur-\nCompression stockings improve venous           gical techniques have replaced more\nhaemodynamics by decreasing venous             traditional large-incision phlebectomy. For\nreflux and reducing ambulatory venous          varicosities in the greater and lesser\nhypertension. Because of limited,              saphenous veins, endovenous techniques\nrandomised, controlled trial evidence, the     have largely replaced traditional large-\nimpact of compression stockings on             incision surgical stripping and vein ligation.\nprogression or recurrence of varicose          Surgical stripping is associated with vari-\nveins remains unclear.10 A multicentre         cose vein recurrence in up to 50\u202f% of\nrandomised, controlled trial of active         patients by five years, most often as a\nversus placebo compression stockings           result of incomplete phlebectomy, persis-\nsuggested that routine use of compression      tent venous reflux, or neovascularisation.\nstockings may not prevent post-throm-          Complications of surgical stripping include\nbotic syndrome in patients with first          extensive ecchymosis and scarring,\nproximal deep vein thrombosis.11 Patients      haematoma, lymphocele, infection,\nshould be instructed to don compression        nerve injury, and deep vein thrombosis.\nstockings in the morning and can remove\nthem at night before going to bed.             ENDOVENOUS THERAPY\nGraduated compression strength is              Endovenous therapy with either radiofre-\nprescribed to treat larger varicosities and    quency or laser ablation relies on thermal\ngreater severity of symptoms and chronic       injury to cause thrombotic and fibrotic\nvenous insufficiency. Unfortunately, the       closure of the saphenous veins in patients\nrate of nonadherence to compression            with documented superficial venous\nstocking regimens approaches 60\u202f% in           reflux. Local tumescent anaesthesia is\npatients with chronic venous disease,          required for patient comfort, to separate\nincluding varicose veins.9                     the vein from the skin surface, and to\n                                               protect surrounding tissue from heat injury.\nPHARMACOTHERAPY                                A systematic review demonstrated that\nVery few drugs help to treat varicose          three-year estimated pooled success\nveins. Diuretics are commonly prescribed       rates of endovenous therapies for saphe-\nfor oedema, but generally do little to         nous varicosities were 84\u202f% for radio-\nrelieve the pain or discomfort. Horse          frequency ablation and 94\u202f% for\nchestnut extract has been shown to             endovenous laser ablation, compared\ndecrease oedema by increasing venous           with 78\u202f% for surgical stripping.9 Long-term\ntone and venous flow. In a randomised,         randomised, controlled trial data have\nplacebo-controlled study,12 horse              established endovenous therapy as an\nchestnut extract was compared to               effective and durable alternative to\ncompression stockings. Patients wearing        surgical stripping. In a randomised,\ncompression hose or taking the horse           controlled trial comparing endovenous\n\n                                                              HANDBOOK OF GERIATRIC MEDICINE","","","","","","","","","","","","","","","","","","","","","","","","","","Incontinence in ageing individuals 201\n\nn\t Pelvis examination should look for                   should be prescribed in elderly        TREATMENT APPROACHES\n    atrophic changes, prolapse and rectal                women.3\n    examination to evaluate the prostate        \t \u2013\tThe underlying causes of\n                                                         incontinence lead to a gradual\nn\t U rinalysis for: bacteriuria, haematuria,            increase in residual urine in the\n    protein and glucose.                                 bladder, often resulting in recurrent\n                                                         urinary tract infections. These\nPathology tests should include urea and                  infections should be treated with\ncreatinine, blood glucose and urine                      an antibiotic and the appropriate\ncytology.                                                symptomatic medication.\n                                                \t \u2013\tMedical treatment should be as for\n  A note of caution \u2013 although the assess-               benign prostatic hyperplasia.\nment must be comprehensive, it must be          n\t Skin-care regimens to protect skin\nas minimally invasive as possible because           integrity and prevent skin infections\nof embarrassment and apprehension in                and urine dermatitis are very\nthe elderly. So focus on the \u201cmust know\u201d            important in the elderly.\nrather than the \u201cnice to know\u201d.3                n\t Surgical interventions: If improvement\n                                                    is insufficient, surgery needs to be\nMANAGEMENT OF URINARY                               considered and can take the form of\nINCONTINENCE                                        an anterior vaginal repair or a fixation\n                                                    of the bladder neck in its normal\nIn terms of management, and in order to             anatomical position behind the pubic\nsupport independent toileting, it is essen-         symphysis. Treat as for benign prostatic\ntial that the family practitioner                   hyperplasia when medical options\nco-ordinates care by a multi-disciplinary           have failed.\nteam, including an occupational- and a          n\t M anagement of the activities of daily\nphysiotherapist. The successful manage-             living: It is important to mention the\nment of urinary incontinence is based on            availability of the following products to\ntheinformationthatemergedduringtheassess-           those elderly patients with a problem:\nment. When considering the manage-              \t \u2013\tDisposable or re-usable absorbent\nment, the following options need to be                   undergarments, underpads and\ntaken into account:                                      bed-pads for heavy leakage\nn\t Behavioural therapy, including              \t \u2013\tFeminine hygiene products for\n                                                         urine containment in cases of light\n    changing the drinking- and bladder-                  and infrequent urine loss\n    emptying habits, are important.             \t \u2013\tBedside commodes or urinals\nn\t Pelvic floor rehabilitation in the form of\n    pelvic muscle exercises (Kegel              CONCLUSION\n    exercises) is very useful mainly in stress\n    incontinence, even in the older             There are probably few things as satisfying\n    individual.                                 as having an elderly patient confirm that\nn\t Pharmacological options are mainly for      simple behavioural changes, including\n    stress and urge incontinence and of         time voiding, urge inhibition and pelvic\n    little use in overflow incontinence.        muscle exercises, have resulted in a\n    Pharmaceutical agents should be tried       marked decrease in both incontinence\n    if behavioural treatment is                 and nocturia. This is, however, only\n    unsatisfactory.                             possible if the family practitioner is aware\n\t \u2013\tThese drugs include anticholinergic        of the high prevalence of the problem in\n                                                the elderly, and applies a whole-person\n         agents tolterodine 1 or 2\u202fmg twice     approach in the evaluation and manage-\n         daily or oxybutynin 2,5-5\u202fmg up to     ment of the problem.\n         four times daily. The use of these\n         drugs may be limited by their side                    HANDBOOK OF GERIATRIC MEDICINE\n         effects of dry mouth, constipation\n         and confusion.\n\t \u2013\tSystemic or topically oestrogens\n         reverse the urogenital atrophy and","202 URINARY SYSTEM CONDITIONS\n\nREFERENCES                                                  women aged 50 and over. Acta Obstet\n1.\tLekan-Rutledge D. Urinary Incontinence                 Gynecol Scand. 2005;84:72.\n                                                      3.\tMerkelj I, Quillen JH. Urinary incontinence\n      strategies for frail elderly women. Urol Nurs.        in the elderly. South African Med J.\n      2014;24(4).                                           2001;94(10).\n2.\tOskay UY, Beji NK, Yalcin O. A study on\n      urological complaints of postmenopausal\n\nHANDBOOK OF GERIATRIC MEDICINE","Cancer screening in the elderly patient \u2013 general guidelines 203\n\nCancer screening in the elderly                                                                   TREATMENT APPROACHES\npatient \u2013 general guidelines\n\nDr D Eedes                                           In the main, we have to extrapolate the\nMBChB FFRAD(T) (SA)                                  data for younger patients to guide us.\n\uf072\t Clinical Oncology Advisor, Cape Town              Once again, the art of medicine is in\n                                                     understanding the potential pros and\nPatient care administered at the extremes            cons of screening, and matching these to\nof life, to the young and the old, is charac-        the individual patient\u2019s expectations and\nterised by unique issues associated with             preferences.\npaediatrics and geriatric medicine. The\nspecial vulnerabilities of these groups are            For the older patient, individualised\naccentuated when it comes to cancer                  screening or surveillance is generally\nprevention, screening, early detection and           recommended.\ntreatment. Paediatric oncology is well\nstructured to deal with the special prob-            CANCER SCREENING\nlems associated with cancers of childhood.           GOALS OF CANCER-SCREENING\nWhile most general oncologists consider\nthemselves prepared to deal with the older           The goal of cancer-screening should be to\ncancer patient, the current growth of the            identify at an early stage an asympto-\ngeriatric population has led to the devel-           matic patient at risk of developing a\nopment of specialised geriatric oncologists          cancer or to detect the cancer at a pre-\nin some parts of the world.                          clinical stage where early treatment\n                                                     would extend the patient\u2019s life by cure as\n  The issues, complexities and limitations           well as improve the quality of that\nof cancer screening in the older patient             extended life.\nare examined in this article.\n                                                     POTENTIAL PROBLEMS OF ROUTINE\n  The global elderly population (older               CANCER SCREENING\nthan 60 years) is estimated to grow to               The potential problems from routine\nmore than two billion by 2050. This is an            cancer screening include:\nage group that in most countries will                n\t Over-diagnosis \u2013 the diagnosis of a\nconstitute a large percentage of the\npopulation.1 In the USA, those older than                condition that will never cause a\n65 constitute over 60\u202f% of all new cancer                patient symptoms or death during his\/\ncases.2 While most cancer clinical trials                her lifetime\nlimit the upper age range to 65, there are           n\t Misdiagnosis\/inaccurate\/indeterminate\nmoves to redress this imbalance.                         test results \u2013 false positive, false\n                                                         negative or inaccurate test results\nCLINICAL TRIALS AND THE ELDERLY                      n\t P sychological impact of a diagnosis \u2013\n                                                         the negative emotional impact of the\nClinical trials very often limit the upper and           diagnosis of a potentially life-\nlower limits of age and usually exclude                  threatening disease\npatients below 18 and over 65. Accruing              n\t Morbidity of screening tests \u2013 the\nolder patients into clinical trials is difficult in      physical and financial burden of\nview of comorbidities, socio-economic                    undergoing a screening test\nfactors and in some cases, ethical issues.           n\t P roblems of treatment \u2013 the side\nEven though the elderly constitute an ever-              effects of a treatment that may\nincreasing percentage of the population,                 negatively affect the patient\u2019s quality\nreliable data regarding benefits of cancer               of life\ntherapies are lagging in this group.                 n\t P atient preference regarding\nPopulation studies which look at issues                  screening that is not taken into\nsuch as screening are particularly poor in               account.\ndata for the over-65 age group.3,4\n\n                                                     HANDBOOK OF GERIATRIC MEDICINE","204 ONCOLOGY SCREENING AND CARE\n\nRISK VERSUS BENEFIT OF CANCER                   younger patient, be they physiological,           C\nSCREENING                                       psychological, social or philosophical.           M\nThe potential damage vs the benefits of         While data from younger population                Y\nscreening for a particular cancer should        groups may be used to guide clinical             CM\nbe kept in mind and be part of any discus-      decision-making, these differences must          MY\nsion with a patient about options. Shared       not be ignored. Addressing the outcomes          CY\ndecision-making where the potential             relevant to the patient has become              CMY\nproblems of a screening test are weighed        central in guiding cancer-screening.              K\nup against the benefits is strongly recom-\nmended. Discussion around the impact of           Geriatric patients often have functional,\na positive test on the patient and around       cognitive and nutritional limitations, as\nthe pros, cons and increased longevity          well as poor social support.7,8 This places a\nattributable to a potential treatment is        greater responsibility on the doctor in\nimportant.                                      terms of informing a patient of the pros\n                                                and cons of any screening intervention.\n  The complexities of patient preparation\nfor some tests (e.g., colonoscopy) as well        There are very few clinical trial data about\nas the logistical issues relating to these      the benefits vs the problems of screening for\ntests should be discussed. The potential        cancer in the older population. As people\nphysical complications of a test should         over 65 are a hetergeneous group, cancer-\nalso be considered, for example, the risks      screening in these patients cannot be based\nassociated with endoscopy or biopsy,            on age alone. Studies suggest that patients\ntaking into account the particular              with a life expectancy of less than 10 years\npatient\u2019s comorbidities.                        will probably not derive a benefit from\n                                                screening for major cancers like breast-,\nCANCER SCREENING                                prostate- and colorectal cancer. However,\nAND THE ELDERLY                                 there is a need for more evidence-based\nCancer is primarily a disease of older adults   guidance in this field.\nand is the second leading cause of death\nin people 65 years or older in the Western        The logistics of the preparation required\nworld. The elderly patient has special char-    for certain cancer-screening tests (fasting,\nacteristics and needs. His\/her variable         bowel prep, and so on) or just getting to\nlevels of fitness, frailty and vulnerability,   and from a screening test itself may be\nrequire a measured approach when                difficult, exhausting and expensive for an\ndiscussing cancer screening, or indeed,         older, frail patient.\nthe potential treatment for a cancer that\nmay be detected. More recently, there             For many older patients, the realities of\nhas been a significant expansion of             the issues around any treatment for\napproaches to treat cancer and, with this,      cancer detected on screening cannot be\nan increase in toxicities and complications.    ignored. Although this may seem obvious,\nA considered approach is required when          it needs to be remembered that it is point-\nembarking on investigations in the asymp-       less performing a screening test on a\ntomatic elderly patient.5,6                     patient who would decline surgical, radia-\n                                                tion or chemotherapy treatments if a\n  The majority of cancer-screening guide-       cancer were indeed detected.\nlines are from evidence derived at\npopulation level and are thus based on            Certain studies in the USA have shown\nstudies that mainly include younger             that patients over 75 and\/or with a limited\npatients. Individual variations in life expec-  life expectancy are undergoing ever-\ntancy, comorbid conditions, functional          higher rates of cancer-screening that may\nstatus or personal preference are gener-        result in harm, including having a negative\nally not addressed in these studies.            financial impact.\n\n  The older patient often has different         FURTHER GUIDANCE\nrisk-benefit considerations from the\n                                                An individualised approach to cancer-\nHANDBOOK OF GERIATRIC MEDICINE                  screening decisions is strongly recom-\n                                                mended. This needs to be done firstly to","","","","","","","","","","","","","","","","","","","","","","","","",""];